

# Combining O<sub>2</sub> High Flow Nasal or Non-Invasive Ventilation with Cooperative Sedation to Avoid Intubation in Early Diffuse Severe Respiratory Distress Syndrome, Especially in Immunocompromised or COVID Patients?

Fabrice Petitjeans<sup>1</sup>, Dan Longrois<sup>2</sup>, Marco Ghignone<sup>3</sup>, Luc Quintin<sup>1\*</sup>

<sup>1</sup> Department of Anesthesia-Critical Care, Hôpital d'Instruction des Armées Desgenettes, Lyon, France

<sup>2</sup> Bichat-Claude Bernard and Louis Mourier Hospitals, Assistance Publique-Hôpitaux de Paris, Paris Cité University, Paris, France

<sup>3</sup> Department of Anesthesia-Critical Care, JF Kennedy North Hospital, W Palm Beach, FL, USA

## ABSTRACT

This overview addresses the pathophysiology of the acute respiratory distress syndrome (ARDS; conventional vs. COVID), the use of oxygen high flow (HFN) vs. noninvasive ventilation (NIV; conventional vs. helmet) and a multi-modal approach to avoid endotracheal intubation ("intubation"): low normal temperature, cooperative sedation, normalized systemic and microcirculation, anti-inflammation, reduced lung water, upright position, lowered intra-abdominal pressure.

Increased ventilatory muscle activity ("respiratory drive") is observed in early ARDS, at variance with ventilatory fatigue observed in decompensated chronic obstructive pulmonary disease (COPD). This increased drive leads to impending then overt ventilatory failure. Therefore, muscle relaxation presents little rationale and should be replaced by lowering the excessive respiratory drive, increased work of breathing, continued or increased labored breathing, self-induced lung injury (SILI), i.e. preserving spontaneous breathing. As CMV is a lifesaver in the setting of failure but does not heal the lung, side-effects of intubation, controlled mechanical ventilation (CMV), paralysis and deep sedation are to be avoided. Additionally, critical care resources shortage requires practice changes.

Therefore, NIV should be routine when addressing immune-compromised patients. The SARS-CoV2 pandemics extended this approach to most patients, which are immune-compromised: elderly, obese, diabetic, etc. The early COVID is a pulmonary vascular endothelial inflammatory disease requiring lower positive-end-expiratory pressure than the typical pulmonary alveolar epithelial inflammatory diffuse ARDS. This leads one to reassess a) the technique of NIV b) the sedation regimen facilitating continuous and extended NIV to avoid intubation. Autonomic, circulatory, respiratory, ventilatory physiology is hierarchized under HFN/NIV and cooperative sedation (dexmedetomidine, clonidine). A prospective randomized pilot trial, then a larger trial are required to ascertain our working hypotheses.

**Keywords:** ARDS, COVID, self-induced lung injury, spontaneous breathing, oxygen high flow nasal

Received: 22 March 2024 / Accepted: 1 August 2024

Published under CC BY 4.0 license

## ■ ABBREVIATIONS AND GLOSSARY

ARDS: acute respiratory distress syndrome

Analgnesia: indifference to pain.

Ataraxia: "imperturbability of mind" (Epicurus) [1]

BP: blood pressure

bpm: breath per minute

C-ARDS: SARS-CoV2 evoked acute respiratory distress syndrome

CCU: critical care unit

\* Correspondence to: L Quintin, 120 Pagere, 69500 Lyon-Bron, France. E-mail: luquintinx@gmail.com

CMV: controlled mandatory ventilation  
 CO: cardiac output  
 COPD: chronic obstructive pulmonary disease  
 Cstat: static compliance:  $V_t/Plat-PEEP$ , with an inspiratory pause (no flow).  
 Cdyn: dynamic compliance:  $V_t/PIP-PEEP$ , without inspiratory pause (with flow); surrogate:  $V_t/\Delta P_L$  [2].  
 CPAP: continuous positive airway pressure  
 Dependent lung: in standing human, basal, non-aerated lung  
 DP: driving pressure  
 $\Delta P_{es}$ : esophageal pressure drop  
 $\Delta P_L$ : tidal change in dynamic transpulmonary pressure  
 Failure: ventilatory failure  
 FRC: functional residual capacity  
 GA: general anesthesia  
 Generator: respiratory generator located in the lower brain stem setting the respiratory rhythm  
 HFN: O<sub>2</sub> high flow nasal  
 HR: heart rate  
 Inspiratory effort: quantified by negative changes in esophageal pressure  
 Labored breathing: continued or intensified labored breathing, heading to ventilatory failure  
 Metaboreflex: “originating in skeletal muscle activated when blood flow to contracting muscles is insufficient to allow both O<sub>2</sub> delivery and metabolite washout” [3]  
 NIV: non-invasive ventilation  
 Non-dependent lung: in standing human, apical, aerated lung  
 PEEP: positive end-expiratory pressure  
 Pendelluft: intrapulmonary gas redistribution from nondependent (better aerated) to dependent lung without  $V_t$  change  
 Pes: surrogate of transpulmonary pressure (alveolar pressure mi-

nus pleural pressure)  
 P/F: PaO<sub>2</sub>/FiO<sub>2</sub>  
 Pplat: pressure measured during brief end-inspiratory hold  
 PS: pressure support, inspiratory assistance  
 P-V curve: pressure-volume curve  
 RASS: Richmond agitation sedation scale  
 RR: respiratory rate  
 Respiratory physiology refers to the brain stem respiratory generator and phrenic activity  
 ROX index:  $(SaO_2/FiO_2)/\text{respiratory rate}$ ; sicker patients require more oxygen and a higher respiratory rate.  
 SB: spontaneous breathing, spontaneous ventilation  
 SILI: patient’s self-induced lung injury  
 SO<sub>2</sub>: oxygen saturation  
 Shunt: perfusion of non-aerated alveoli (low or zero VA/Q [4]);  $Q_s/Q_t = (C_cO_2 - C_vO_2)/(C_cO_2 - C_aO_2)$   
 Strain: lung deformation [5], tidal volume, tidal volume/end expiratory lung volume [6]  
 Stress: transpulmonary pressure [5, 6], driving pressure  
 Transpulmonary pressure: transmural pressure between the inside (alveolus) and outside (pleura-esophagus) of the cavity  
 Upright position: reverse Trendelenburg, head-up +60°, legs down: -45° [7]  
 VA/Q: ventilation/perfusion ratio  
 Venous admixture: intrapulmonary shunt+VA/Q mismatch (low VA/Q areas) [8]  
 Ventilatory physiology refers to lung and chest wall mechanics  
 VHFN: O<sub>2</sub> very high flow nasal  
 VILI: ventilator-induced lung injury  
 VO<sub>2</sub>: oxygen consumption  
 Vt: tidal volume  
 WOB: work of breathing

## ■ INTRODUCTION

This article highlights the pathophysiology of classical vs. COVID-acute respiratory distress syndrome (ARDS), and the use of O<sub>2</sub> high flow nasal (HFN) and very high flow nasal (VHFN >70 L.min<sup>-1</sup>) and inspiratory assistance (pressure support: PS) to avoid endotracheal intubation (“intubation”). This is a follow up of a manuscript devoted to early weaning of invasive ventilation [9]. In the setting of COVID-ARDS, ~41% of the patients received HFN or non-invasive ventilation (NIV) or continuous positive airway pressure (CPAP)

[10], but only ~20% of the patients receive analgesics or sedatives [11]. Indeed, sedation is believed to cause respiratory depression and conceal ventilatory failure (“failure”) i.e. the clinical sign to escalate to more invasive therapy. By contrast, alpha-2 agonists (“cooperative sedation”, rousable sedation: dexmedetomidine, clonidine, etc.) are now considered as first-line sedatives in the critical care unit (CCU) [12-17]: dexmedetomidine eases NIV [18] and halves the occurrence of endotracheal intubation (“intubation”) [19].

CMV is lifesaving [20] when impending or overt ventilatory failure is ominous. Nevertheless, CMV

“(in and of itself) does not produce lung healing” [21]. In multiple-organ failure patients under conventional sedation, CMV is associated with death ranging from 16 to 88 % [22-24] (discussion: [25]). Current management [26] is associated with circulatory disturbances, ventilator-associated pneumonia, excessive sedation, delirium, muscle weakness, immuno-paralysis, etc. Thus, NIV is the first line tool in the setting of immunodeficiency [27, 28] or upon massive influx of elderly patients with baseline chronic inflammation and comorbidities.

Continued or intensified labored breathing (“labored breathing”) [29] leads to impending, then overt failure, additional lung injury (inflammation; self-induced lung injury: SILI [5, 30]; ventilator-induced injury: VILI). Thus, delayed intubation and ventilatory assistance may lead to overt failure, gasping, cardiac arrest and death [30-34].

A multimodal approach [9, 35-40] (“analytical management” [37-41]) hierarchizes the pathophysiology of the autonomic nervous system, the respiratory generator [42-44], the vasomotor center [45], the chest wall and lung mechanics [6, 8], circulation [46], kidney and metabolism. The interval between admission and intubation gives one the opportunity to address labored breathing [29], reduce the inspiratory effort (large negative esophageal pressure change), normalize the work of breathing (WOB), reverse failure, break-up SILI [40] and bypasses intubation. Our hypothesis is: cooperative sedation extends the tolerance to HFN or NIV and buys time for a multimodal approach [35] to normalize the respiratory drive. As this multimodal approach bears many research questions, they are delineated in the appendix.

## ■ PATHOPHYSIOLOGY

### Acute respiratory distress syndrome: pathophysiology

Very schematically, early diffuse ARDS entails alveolar *epithelial* dysfunction. By contrast, early COVID-ARDS entails pulmonary vascular *endothelial* dysfunction [6, 8, 47, 48].

ARDS is a broad entity characterized by severe dyspnea, hyperpnea, tachypnea, hypoxemia, decreased lung compliance (“compliance”), alveolar infiltrates [49], redefined as  $\text{PaO}_2/\text{FiO}_2 = \text{P}/\text{F} < 300/200/100$  with positive end-expiratory pressure (PEEP)=5 cm H<sub>2</sub>O after intubation, bilateral opacities without volume

overload or cardiac failure [23]. This extends to non-intubated patients [50]. These criteria are not perfect [51]. Using PEEP= 10 cm H<sub>2</sub>O, FiO<sub>2</sub>=1 leads to underestimate ARDS [52]. FiO<sub>2</sub>=1 at low PEEP de-recruits alveoli and lowers P/F (196 to 153) [53]. As ARDS entails a spectrum of diseases [54] and several clinical presentations (“phenotype”), a CT scan individualizes management:

#### 1. Typical ARDS

Typical ARDS [6] comprises two entities [55]: early diffuse ARDS entails alveolar epithelial dysfunction, unstable alveoli, fluid-filled alveoli (non-cardiogenic pulmonary edema), bilateral infiltrates that ultimately coalesce into compressive atelectasis. A direct, proportional, relationship exists between the amount of non-aerated tissue and lowered compliance [6]. Typical ARDS is addressed with high PEEP [56], except in the setting of “focal” ARDS [55].

- “focal” ARDS entails extra-pulmonary ARDS, loss of hypoxic vasoconstriction, high compliance and low inflection point on the inspiratory pressure-volume (P-V) curve ( $\leq 5$  cm H<sub>2</sub>O) [55], and is addressed with low PEEP.
- “diffuse” ARDS entails pulmonary ARDS, high dead space and PaCO<sub>2</sub> [57, 58], low compliance [59] (a “baby” lung is small but not “stiff” [60]), high inflection point ( $>7$  cm H<sub>2</sub>O), high mortality and is addressed with high PEEP [56]. High inflection point is related to low end-expiratory volume, low functional residual capacity (FRC) [55] and low PaO<sub>2</sub>.

#### 2. COVID-ARDS

Early COVID-ARDS entails pulmonary vascular endothelial dysfunction [47, 48], pulmonary vascular abnormalities [6], loss of hypoxic vasoconstriction with hyperperfusion of non-aerated, gasless tissue at variance with areas of no-perfusion and normal aeration [6], micro- and macroemboli [47, 48, 61], well aerated lung volume [62], high compliance and low driving pressure (DP) [63]. Intrapulmonary shunt (“shunt”) is perfusion of non-aerated alveoli (low or zero VA/Q [4]). The implication is that a high shunt fraction goes to gasless tissue [62]. Micro-emboli prevent recruited alveoli to participate in gas exchange. Venous admixture is intrapulmonary shunt+VA/Q mismatch [8]. In COVID-ARDS, VA/Q mismatch is more important than shunt i.e., predominantly low perfusion of ventilated alveoli. By contrast, in typical ARDS, shunt is more important than VA/Q mismatch i.e., adequate

perfusion of nonventilated alveoli [8] (COVID-ARDS: high VA/Q and dead space; diffuse typical ARDS: low VA/Q) [63]. In COVID-ARDS, profound hypoxemia [48] occurs when compared to typical ARDS with same compliance. Typical ARDS presents with a higher P/F for the same compliance [6]. Recruitment is highly variable [63]. In the COVID-ARDS setting, low Vt results in increased dead space, reabsorption atelectasis, hypoventilation, hypercarbia, high hypercapnic drive and high sedative requirement. Low Vt-high PEEP conventionally proposed in typical ARDS appears of modest benefit in COVID-ARDS [6, 62].

*Hypoxic vasoconstriction* is relevant given the vascular disease. In pig lung injury, PS ventilation is associated with a redistribution of blood flow toward non-dependent better aerated lung without inducing recruitment. Increased aeration and improved hypoxic vasoconstriction occur in dependent regions [64]. Furthermore, alpha-2 agonists improve hypoxic vasoconstriction [65-67].

The mechanisms observed in early ARDS progress toward fibrosis more rapidly in COVID-ARDS compared to typical ARDS. Consequently, starting from admission, the intensivist is essentially racing against time, contending with ventilatory failure on one front and the rapid progression towards fibrosis on the other.

### Ventilatory failure: impending vs. overt

Upon admission, the clinical presentation involves silent hypoxemia *or* ventilatory muscle dysfunction (“muscle dysfunction”) with labored breathing [10] (Figure 1). This dictates the immediate management whether it be HFN or helmet NIV, respectively.

*Semeiology*: If the use of HFN/VHFN/PS does not quickly alleviate labored breathing, impending failure is an indication for intubation+CMV. There is no definitive index that mandates intubation, but rather continued observation of ongoing or worsening failure. Clinical signs to look for are discomfort, intolerance to the device, mental deterioration, diaphoresis, dyspnea (with hyperpnea being more relevant than tachypnea), increased inspiratory effort, phasic activation of the sternomastoid muscle (palpation of the sternomastoid muscle allows for assessment of the drive in decompensated chronic obstructive pulmonary disease (COPD) [68] and ARDS [69]), use of accessory muscles, tracheal tug [69], thoraco-abdominal swing, suprasternal notch retraction (an index of large negative esophageal pressure swing), intercostal recess-

sion [69], nasal flaring, gasping for air [70], copious respiratory secretions [71], airway bleeding, circulatory instability, electrocardiographic changes, trends in P/F ratio.

*Criteria for intubation* are primarily based on the clinical evolution. Labored breathing [29], overt failure [21], continuing hyperpnea ( $V_t > 9.6-12 \text{ mL/kg-1}$  [72]) or absence of reduction of esophageal change  $< 10 \text{ cm H}_2\text{O}$  [2] are ominous signs.  $RR > 30-35 \text{ min-1}$ ,  $\text{SaO}_2 < 88\%$  are only contributive. Tachypnea is a response to lung inflammation but does not alone justify intubation [21]. In the setting of HFN, even minimal tachycardia is a sign of failure (intubation:  $\text{HR} = 108 \pm 19$ ; not intubated:  $104 \pm 19$  beats per min [33]).


#### 1. Silent hypoxemia

Hypoxemia results from reduced O<sub>2</sub> diffusion (typical ARDS) or inadequate alveolar perfusion (COVID-ARDS: micro- or macroemboli [48]) and is not necessarily accompanied by muscle dysfunction and signs of ventilatory failure, e.g., during “silent hypoxemia” [73-75]. Isolated hypoxemia without labored breathing is addressed with HFN/VHFN. Nevertheless, prolonged silent hypoxemia may lead to clinical deterioration, continued labored breathing, and eventually intubation.

#### 2. Clinical evolution

The present opinion regarding *clinical* evolution aligns with recent guidelines on the use of HFN/NIV in the context of COVID (Table 1 [76]). One notable difference worth discussing is the emphasis on  $\text{SaO}_2 > 92\%$  in the consensus paper [76], while others differentiate requirements based on P/F [23, 50]. Some experts [20, 21] stress the importance of observing the evolution of clinical signs, such as hyperpnea rather than tachypnea, over relying on oxygenation parameters. Intubation decision is not based upon  $\text{SaO}_2$  or  $\text{PaO}_2$  values [20, 21], or segregation with P/F [23, 50]. The indices help in identifying NIV failure within 2 h of treatment initiation [2, 72, 77] (HFN: ROX index: NIV; HACOR; table 1 in [10]). Subsequent observation is performed on an hourly basis. (Figure 1). Silent hypoxemia is a contributing factor to this approach. Additionally, hypoxemia acts as a short-acting, unsustainable stimulus, known as “hypoxic ventilatory decline,” which primarily heightens the response to acidosis or hypercapnia [9, 74]. For instance, even when  $\text{SaO}_2 \leq 70\%$ , a  $\text{PaCO}_2$  of approximately 32 mm Hg (end-tidal  $< 29 \text{ mm Hg}$ ) can prevent the hypoxic response [74]. Therefore, the conventional threshold ( $\text{PaO}_2$





**Fig. 1. From non-invasive to invasive ventilatory assistance in the setting of severe ARDS.**

The clinical signs of ventilatory failure are: discomfort, intolerance to device, mental deterioration, diaphoresis, dyspnea (hyperpnea> tachypnea), inspiratory effort [use of accessory muscles, phasic activation of the sternomastoid muscle (palpation of the sternomastoid muscle as an index of drive in ARDS [69]), tracheal tug [69], thoraco-abdominal swing, suprasternal notch retraction (index of large negative esophageal pressure change), intercostal recession [69], nasal flaring, gasping [70]], copious respiratory secretions [71], airway bleeding, circulatory instability, electrocardiographic changes, P/F trend. An index of drive, airway occlusion pressure (P0.1), is set to 0.5 ms in the spontaneous breathing setting (P0.5) [125] and used as such.

*Isolated “silent hypoxemia” without signs of labored breathing as the principal symptom:* HFN/VHFN is the logical therapy. A multimodal approach complements HFN/VHFN to allow for an extended period of optimization and observation.

*Labored breathing as the principal symptom:* continued or intensified labored breathing should be interrupted to avoid transitioning from impending to overt failure and arrest. HFN/VHFN allows one to simultaneously buy time, observe, carry on the ancillary work (insertion of lines, chest X Ray, ECG, CT scan, bronchoscopy, pleural-pulmonary-cardiac ultrasounds, etc.) and addressing hypoxemia. Repeated assessments of the tidal volume (under mask NIV) and other signs of ventilatory failure or nasal/esophageal pressure [70] changes will allow one to assess improvement or deterioration within 2 h (NIV failure vs success respectively: Vt: 9.6-12 vs. 7.6-10.2 mL.kg<sup>-1</sup> with NIV set to Vt=6-8 mL.kg<sup>-1</sup> [72]; NIV success: reduction in esophageal pressure change≥10 cm H<sub>2</sub>O [2]; nasal pressure change mirrors esophageal pressure change [70]). Criteria for escalation from HFN to NIV are P/F<100, and/or RR>25 bpm, and/or respiratory distress and dyspnea despite HFN>60 L.min<sup>-1</sup> [70]. Absence of improvement or deterioration within 2 h suggests switching to helmet NIV to achieve higher PEEP, restore a fluid-like lung behavior and reduced work of breathing. Absence of improvement or deterioration implies running through a multimodal approach again, looking for sepsis, coronary artery, delirium tremens, etc., then escalating up to intubation+CMV and avoiding overt failure.

NIV is set to avoid dyssynchrony: low inspiratory trigger, high pressurization time, lowest expiratory trigger. Helmet NIV requires faster pressurization time≤50 ms, cycling off=30% of peak inspiratory flow, higher PS level (+33-50%) and PEEP. High inspiratory assistance should not sum up with negative esophageal pressure change to avoid high transpulmonary pressure and further inflammation. HFN or NIV allows one to buy time and combine physiological tools (circulatory, respiratory, ventilatory, autonomic) within a multimodal approach. The check list is (Vt, RR)=f(temperature, agitation, cardiac output, microcirculation-arterial lactate, inflammation, lung water-diuresis, systemic pH, PaCO<sub>2</sub>, PaO<sub>2</sub>):

1) fever control [156, 157]: 36<θ<35°C, i.e. first [paracetamol, wet sheet+fan or BairHugger®] then alpha-2 agonist (“no bolus, start slow-go slow, fill them up-then open them up”); dexme-

detomidine or clonidine up to 1.5 or 2 µg.kg<sup>-1</sup>.h<sup>-1</sup>, respectively). Alpha-2 agonists develop favorable effects slowly (≥3 h) if a slow administration is used to avoid bradycardia or hypotension, after iterative echocardiographic assessment and passive leg raising.

2) agitation [167] addressed to stringent quietness (-2<RASS<0; cooperative sedation: alpha-2 agonist as first-line sedative [15]; “breakthrough”: haloperidol 2.5-10 mg bolus or 5 mg bolus up to 4 administrations; supplementation: infusion up to 50 mg/day).

3) normalized cardiac output [4, 46]: iterative echocardiography coupled with volume, vasopressors, inotropes, pulmonary vasodilators.

4) normalized microcirculation and pH (systemic and regional): the alpha-2 agonist normalizes the sympathetic vascular activity, revascularizes the microcirculation, normalizes the local pH and arterial lactate and inflammation linked to acidosis.

5) anti-inflammation (source control; alveolar antiinflammation: adequate PEEP to suppress atelectrauma; systemic indirect antiinflammation i.e., alpha-2 agonist, steroids).

6) reduced lung water: volume loading before PEEP and administration of alpha-2 agonists then according to clinical signs, lowered PCWP [241] or iterative echocardiography. Increased CO or BP upon passive leg raising does not necessarily imply further volume loading. Only peripheral perfusion dictates volume load: mottling, capillary refill time, diuresis, lactate, pH, CO<sub>2</sub> gap, mixed venous saturation. The alpha-2 agonist produces anti-ADH effect, diuresis and kaliuresis.

7) normalized CO<sub>2</sub>: lowered activity of the respiratory generator and inspiratory muscles through fever control (36<θ<35°C), microcirculation and pH with an alpha-2 agonist. PS level is as necessary to suppress the additional work of breathing caused by the valves and tubings (3-7 cm H<sub>2</sub>O) [116].

8) normalized hypoxic drive [78]: Oxygen therapy is the first line upon admission. a) FiO<sub>2</sub>=1 as briefly as possible (absorption atelectasis, toxicity) lowered step by step to 0.4, without lowering the flow, i.e. keeping PEEP on. Normalization of systemic CO<sub>2</sub> and pH are key before normalizing the hypoxic drive. b) PEEP according to the disease : focal ARDS : 5 cm H<sub>2</sub>O; COVID-ARDS: 8-10 cm H<sub>2</sub>O; diffuse ARDS: 16 cm H<sub>2</sub>O. An esophageal balloon individualizes PEEP as early as possible. Leaks in the setting of NIV limit the ability to use very high PEEP.

9) upright position [7]: reverse Trendelenburg, 60° head up, 45° leg down. Upright position makes compression stockings or military antishock trouser sometimes useful.

10) lowered intra-abdominal pressure: gastric and bladder decompression, increased colonic motility (mild laxative).

Abbreviations: HFN: O<sub>2</sub> high flow nasal; VHFN: very high flow nasal; NIV: non-invasive ventilation; CMV: controlled mandatory ventilation; PEEP: positive end-expiratory pressure; PS: pressure support, inspiratory assistance.

**Table 1. Criteria for non-invasive ventilatory failure [76]**

- Absence of improvement or worsening of clinical signs observed on admission, including oxygenation data and increased respiratory rate
- Appearance of signs of ventilatory muscle fatigue or use of accessory muscles
- Presence of acidosis, both respiratory and metabolic
- Inability to properly clear respiratory secretions
- Signs of circulatory instability, including hyperlactatemia
- Deterioration of consciousness or presence of seizures
- Intolerance to device, especially mask wearers

> 55-60 mm Hg, with SaO<sub>2</sub> > 92%) provides only a rough estimate, indicating merely the flat portion of the O<sub>2</sub> dissociation curve. Nevertheless, being outside this flat portion does not necessarily mandates intubation. The initial line of therapy focuses on restoring oxygenation and normalizing the hypoxic drive [78], which may not immediately necessitate intubation but instead requires close observation looking for worsening failure and a multimodal approach.

Muscle dysfunction involves overly active muscles. In contrast to the acute over chronic fatigue seen in COPD, muscle function in ARDS is typically intact at baseline, i.e. prior the onset of ARDS. However, muscle failure can occur due to various factors, including a) septic dysfunction [79], b) acute cardiac failure leading to exhaustion and death [80], and c) prolonged evolution (as mentioned above).

In early ARDS, a high inspiratory activity (“respiratory drive”, “drive”, “neural demand” [42, 43]) impinges upon intact muscles. A high muscular activity of intact muscles requires transpulmonary pressure to be addressed specifically (low inspiratory assistance, low pressure support: PS using upfront helmet NIV). This contrasts with acute over chronic fatigue of muscles observed in decompensated chronic COPD with reduced CO<sub>2</sub> excretion: in the setting of COPD, unloading the muscles is necessary for hours or days with high PS to overcome fatigue and decompensation [68]. By contrast, high PS is inappropriate for ARDS.

### 3. Respiratory drive

Respiratory and ventilatory physiology refer to brain stem processes vs. lung and chest wall function, respectively. Located in the lower brain stem, apposed to the vasomotor center, the respiratory generator (“generator”) controls the respiratory rhythm and phrenic activity and integrates the myriads of factors leading to the drive and the activation of the ventilatory muscles:  $(V_t, RR)=f(\text{temperature, agitation, cardiac output,}$

$\text{microcirculation, inflammation, lung water-diuresis, systemic pH, PaCO}_2, \text{PaO}_2$ ; Equation 1, to be used as a check list). ARDS patients present with a high drive, ventilatory muscular activity, inspiratory peak flow (“air hunger”) [2, 72, 81, 82], transpulmonary pressure, inflammation, labored breathing and impending failure. The higher drive present in COVID-ARDS patients led away from light sedation and spontaneous breathing (SB) [83-85], back to deep sedation, paralysis, protective ventilation and proning. As emphasized early April 2020 physiology was at loss in a bewildered world ([francais.medscape.com/voiararticle/3605845?=&null&icd=login\\_success\\_email\\_match\\_fpf&form=fpf](https://www.medscape.com/voiararticle/3605845?=&null&icd=login_success_email_match_fpf&form=fpf)). Dissecting and normalizing the myriads of factors [35, 74] involved in the genesis of hyperpnea and tachypnea allows one to lower the drive immediately following admission (“multimodal approach” [35]). Normalized drive rests on a functional generator at variance with the suppressed activity of the generator and suppressed drive caused by general anesthesia+paralysis.

### 4. PEEP

As oxygenation is not the key issue anymore in ARDS [21, 35], the rationale for using high PEEP does not rest on oxygenation. Poor oxygenation (P/F<150) is *unassociated* with the increased inspiratory activity [2] but with inflammation [86].

In the setting of diffuse alveolar damage, solid-like behavior leading to pendelluft, increased spontaneous ventilatory effort [35, 87], atelectrauma, WOB and SILI are to be avoided. High PEEP prevents cyclic collapse of the bronchiolar tree [88] or of alveoli (atelectrauma) [89], thus suppresses the mechanical inflammation (SILI or VILI). As observed during the first breath after birth (-70 cm H<sub>2</sub>O [90]), the first inflation of a kid’s balloon requires very high transmural (transalveolar) pressure; further inflation requires minimal incremental pressure. Once inflated by ad-

equate PEEP, the “baby lung” in adult ARDS operates on the highest slope of the *expiratory* [91] P-V curve (highest compliance). The lung switches from solid- to fluid-like behavior [2], with a reduction in esophageal pressure changes and DP. The low PEEP achieved with HFN/NIV cannot recruit all atelectatic, non-aerated, areas. The objective is only to improve low VA/Q areas [92, 93], at variance with fully reopening the lung [94, 95] and correcting entirely the intrapulmonary shunt. Such a minimalist objective requires much lower PEEP levels. If so, “protective” ventilation is not protective because of low Vt, but because of PEEP and reduced solid-like behavior, WOB, pendelluft [87] and atelectrauma. Recruitment increases resting volume and FRC, lowers DP and decreases lung deformation (strain [5], Vt/end-expiratory lung volume ratio [6]). By contrast, low PS, Vt and transpulmonary pressure minimizes stress [5, 6]. In addition, under SB, the active diaphragm keeps the alveoli open during a longer expiratory interval [96], synergistically with PEEP.

The low PEEP achieved with HFN/VHFN/NIV may suit the relatively high compliance and low PEEP requirements observed in the setting of early COVID-ARDS [61, 63] and focal ARDS. PEEP is set as a function of the considered disease, using various techniques a) immediately following admission, a “one size fits all” approach uses the ARDS network table [97, 98]. Evidently, leaks observed in the setting of mask NIV would not allow setting the highest PEEP levels. This bears little consequences in the setting of focal ARDS or COVID-ARDS as lower PEEP levels are required when compared to diffuse ARDS. b) given a CT scan, rules of thumb are useful: “focal” ARDS: ~5 cm H<sub>2</sub>O; diffuse ARDS: ~10 cm H<sub>2</sub>O [55]; mild vs. severe: 5-10 vs. 15-20 cm H<sub>2</sub>O [98]; COVID-ARDS: 8-10 cm H<sub>2</sub>O [48] c) titrated to respiratory compliance [8] (COVID : avoid overdistension, increased dead space, hypercarbia and heightened drive; typical ARDS: recruitment of perfused units: low VA/Q, and increased compliance d) as soon as possible, an esophageal balloon individualizes PEEP [99, 100] in SB patients [2, 70]. e) impedance tomography or lung echography combined to arterial and venous gases and echocardiography are another option.

## Limits of controlled mechanical vs. spontaneous ventilation

### 1. Limits of controlled mechanical ventilation

ARDS is managed [26] using intubation, general anesthesia [101] (GA renamed “deep sedation” [102],

analgesia-sedation), paralysis [103], proning [22] and low DP [104]. Nevertheless, this is *not* a treatment for ventilatory failure [21]: CMV only buys time [49] for self-healing [21, 105] of the alveolus or of the capillary. Many issues are unsettled:

- a. despite remarkable results [103], paralysis should be used sparingly, e.g., high drive [106].
- b. deep sedation is associated with ventilator-to-patient dyssynchrony [107] and death [85] in ARDS patients [108].
- c. no comparison of SB vs. paralysis [109] has been published. SB with airway pressure release ventilation [110, 111] is not discussed. Three issues are to be considered:
  - i. no trial addresses the various Vt in the setting of ARDS (2, 4, 6, etc. mL.kg<sup>-1</sup>; appendix). The only evidence is the retrospective linear association between improved outcome and lowered DP < 14 cm H<sub>2</sub>O [104].
  - ii. proning: That many humans sleep in the prone position is not an argument for awake proning in early COVID-ARDS: humans move freely from supine to prone and back during sleep, at variance with imposed prolonged proning in a CCU environment with discomfort.

The excellent epidemiological result [22] is methodologically weak. First, the results are not segregated between P/F < 100 vs. < 150, mixing severe and moderate ARDS. Second, no comparison exists between supine vs. prone vs. lateral+prone+lateral positioning; *multiple* repositioning is presumably the key to address compressive atelectasis, but not necessarily proning itself. Third, P/F returns towards baseline after turning supine, with no comparison to supine group (figure S2 [22]). The *cause* of ARDS is unaltered by proning; a rescue therapy causes no miracle. Simply the number of patients requiring proning progressively decreases, improved by multiple repositioning.

Mechanically, collapse is a function of the hydrostatic pressure imposed on the alveolus (i.e. the weight of the heart on the left lung). Thus, proning opens more non-dependent dorsal zones than it collapses in dependent sternal regions [112]. Indeed, proning leads often to a small improvement in PaO<sub>2</sub> [62], due to better VA/Q matching in vaso-dysregulated tissue [6] or perfusion redistribution in response to pressure or gravity [62] but not to alveolar recruitment. Given high compliance, minimal P/F improvement linked to CCU proning presents minimal interest in the setting

of early COVID-ARDS, imposing on limited staff resources ([6] “responders”: P/F increase >20 mm Hg in 75% of the patients; [62, 113]). In intubated patients, proning vs. upright position increases P/F to a similar extent in patients with the lowest P/F (moderate and severe ARDS, panel B, *Appendix* vs. table S8 [7, 22]). Proning used in the setting of intubated paralyzed patients [22] was extended to awake non-intubated patients in the setting of early COVID-ARDS. Given these limitations, proning in awake non-intubated patients may avoid intubation [8].

- iii. SB: Severe ARDS in *single*-organ failure patients managed with early SB under cooperative sedation carries a ~8.5% mortality in COVID-ARDS [39].
- iv. absence of sedation: Passive hyperventilation below the apnea threshold *without* sedation carries a low mortality in COVID-ARDS [114].
- d. the absence of a prone vs. upright position trial (reverse Trendelenburg, head-up +60°, legs down: -45°) [7].

These weaknesses leave recommendations [26] with shaky foundation [115]: “*loss of muscle tone... caused by muscle relaxants, anesthetics, and sedatives, and the use of high oxygen concentration in inspired gas are the prerequisites to produce atelectasis in... healthy subject during anesthesia. This... common treatment in ARDS... adds to the collapse and consolidation caused by the disease itself*”.

## 2. Limits of spontaneous breathing

- a. CPAP vs. inspiratory assistance: HFN provides CPAP and increased end-expiratory volume *without* inspiratory assistance. Thus, it does *not* unload the inspiratory muscles. If a high drive is not normalized early, and given the load imposed by the valves and tubing [116], this absence of unloading may progressively cause acute fatigue of intact muscles, requiring switching to PS or CMV to prevent progression to failure.
- b. High vs. low inspiratory assistance: The high inspiratory effort, and  $V_t$ , is influenced by inflammation and drive but independent of the level of inspiratory assistance (PS level) [72, 117]. A high inspiratory effort manifests as hyperpnea, hypocapnia, a large inspiratory esophageal pressure drop ( $\Delta P_{es}=26-40$  cm H<sub>2</sub>O) and low dynamic compliance ( $V_{te}/\Delta P_L$ ) [2]. Excessive inspiratory assistance further amplifies the inspiratory esophageal pressure change, the transpulmonary pressure [81, 118],  $V_t$ , atelectrauma, and inflammation. Therefore, inspiratory assistance is required only to alleviate the WOB caused by the

ventilatory apparatus rather than to unload the muscles (valves, tubings; PS=3-5 cm H<sub>2</sub>O [116]). More, inspiratory assistance cannot alleviate solid-like behavior, atelectrauma and mechanical inflammation. Adequate PEEP can achieve this when the lung is at its optimal compliance. Setting PS to achieve a  $V_t=7-10$  mL.kg<sup>-1</sup> [33] will completely unload the ventilatory muscles but may be detrimental because the baby lung does not tolerate such high  $V_t$  [119]. Rather, esophageal [2] or nasal [70] pressure changes should be limited. Therefore, an uncontrollable drive leading to labored breathing and increased WOB does not necessitate increased PS but rather a reduction in drive, with early initiation of helmet NIV [82, 120]. Failed NIV is defined as the absence of reduction in  $\Delta P_{es}<10$  cm H<sub>2</sub>O within 2h (reduced dyspnea and hyperpnea i.e., success:  $\Delta P_{es}=8-15$ ; failure: 30-36 cm H<sub>2</sub>O) [2]. Accordingly, increased  $V_t>9.6-12$  mL.kg<sup>-1</sup> is the hallmark of early NIV failure [72]. NIV failure is associated with death either because of uncontrollable drive in a very sick patient [20], or a too high PS level. By contrast, successful NIV require close observation with early escalation only if continued labored breathing persists: HFN, VHFN, mask NIV, helmet NIV (Figure 1).

## ■ OXYGEN HIGH FLOW NASAL AND NON-INVASIVE VENTILATION

### Oxygen high flow nasal

Classical [121] or updated [122, 123] Optiflow™ help normalizing labored breathing while simultaneously addressing the ancillary work (figure 1) and a multimodal approach [35]. In the setting of early ARDS, HFN takes precedence over NIV [124], with certain caveats [82, 120]. HFN increases CO<sub>2</sub> wash-out and dynamic compliance, comfort, oxygenation [125] and clearance of secretions [10]. HFN reduces inspiratory effort, CO<sub>2</sub> production and RR due to a resistive effect and prolonged expiration. The degree of improvement correlates with the flow rate and PEEP, leading to increased FRC, restored fluid-like behavior, and decreased inspiratory WOB. For instance, administering HFN at 50 L.min<sup>-1</sup> to patients in septic shock diminish the respiratory drive (P 0.5) and esophageal pressure change [125].

With HFN, O<sub>2</sub> flow up to 60-80 L.min<sup>-1</sup> is achieved through conventional Optiflow or a ventilator. Modified Optiflow can administer up to 120 L.min<sup>-1</sup> [123]: two blenders into one nasal prong convey a very high



flow (VHFN; 1.5 mL.kg<sup>-1</sup> [123]). In healthy volunteers, the mean airway pressure ranges from ~3 to ~12 cm H<sub>2</sub>O, generating PEEP (35 L.min<sup>-1</sup>: range: 1.5-5.3 cm H<sub>2</sub>O; 100 L.min<sup>-1</sup>: range: 7.3-16.2 cm H<sub>2</sub>O [121, 122]). In the setting of early focal and COVID-ARDS, this may allow enough recruitment to avoid intubation when silent hypoxemia without labored breathing is the principal derangement. However, VHFN appears poorly tolerated after 20 min [123]. The reason is unclear: poor humidification? high expiratory resistance and expiratory WOB [123]? This leads to the combination of discontinuous NIV and discontinuous HFN, making the technique complex and possibly inadequate to avoid intubation.

In the setting of acute failure, high inspiratory peak flow leads to room air entrainment under HFN. Exercise generates a peak inspiratory flow up to 255 L.min<sup>-1</sup> [126, 127] and mimics the peak flow observed during acute failure [127]. A challenge is to match such a high peak inspiratory flow. Simple tools minimize air entrainment, either alone or combined:

- A simple surgical mask applied over the mouth in addition to HFN 60 L.min<sup>-1</sup> decreases the RR (28 to 26 breaths per min: bpm), increases the PaO<sub>2</sub> (59 to 79 mm Hg) and P/F (83 to 111) [128]. Adding a “double trunk” mask without adding O<sub>2</sub> to HFN=40-60 L.min<sup>-1</sup> increases PaO<sub>2</sub> (63 to 88 mmHg in 11 responders out of 15 patients) [129].
- in healthy volunteers, HFN 50 L.min<sup>-1</sup> within a standard helmet achieves stable high PEEP=8 cm H<sub>2</sub>O and increases CO<sub>2</sub> washout (PetCO<sub>2</sub>=33 mm Hg) [130].
- in addition to the nasal prong, insertion of up to 2 prongs through the mouth can achieve O<sub>2</sub> flow~120-180 L.min<sup>-1</sup>. In our experience, two classical Optiflow prongs, oral and nasal, achieves O<sub>2</sub>~120-140 L.min<sup>-1</sup> and high SaO<sub>2</sub> (Quintin, unpublished data).
- cooperative sedation (above: 2<RASS<0) evokes indifference to CCU stimuli and lowered VO<sub>2</sub>, enhancing tolerance to continuous HFN/NIV, noise, humidification, and nasal prong(s) for days.

### Non-Invasive ventilation

Labored breathing and fatigue lead to NIV, which is a consequence of either continued or increased drive or to the absence of any inspiratory assistance with HFN/VHFN. Criteria for escalation to NIV are P/F<100, and/or RR>25 bpm, and/or ventilatory distress and dyspnea despite HFN>60 L.min<sup>-1</sup> [70].

*Ventilator-to-patient dyssynchrony:* Using NIV, the key issue is to adapt the ventilator to the patient, not the opposite [132]. First, inspiratory effort occurs during early inspiration, especially when high inspiratory activity occurs and low flow settings are used [133]. Patient-ventilator dyssynchrony occurs only if the ventilator's inspiratory assistance is suddenly lost during continued inspiratory muscle contraction [134]: the more intense the drive, the higher the flow requirement [135]. Second, the ventilator's inspiratory cycle should stop immediately before the beginning of the patient's expiratory effort [133].

#### 1. Mask NIV

To our surprise, with a tightly adjusted mask, Drager ventilators (Evita XL, Infinity V500) combined to cooperative sedation allows for achieving PEEP up to 20 cm H<sub>2</sub>O with minimal leaks, for days [136]. Despite leaks and tolerance issues, since the pathophysiology of ARDS differs only in the amplitude of the dysfunction in intubated vs. non-intubated patients and the literature is limited, parameters set under invasive ventilation are used [9, 36, 37, 40]:

- a. *PEEP* is set on a patient-per-patient basis given the heterogeneity of ARDS. Leaks lower PEEP; however, the patients treated with NIV are less severe or present to the CCU earlier in the evolution of their ARDS. An esophageal balloon inserted as early as possible allows for observing reduced esophageal pressure change ( $\Delta P_{es}$ <10 cm H<sub>2</sub>O [2]) and improved labored breathing. In some patients, NIV appears successful within minutes when high PEEP combines with low PS [136], possibly restoring fluid-like behavior.
- b. *PS:* Under PS, plateau pressure (P<sub>plat</sub>) is measured during a brief inspiratory hold in intubated patients [137]. NIV was initially used in the setting of acute decompensation of COPD with muscular fatigue, and thus requiring high PS amplitude. As the patient population has switched from COPD [68] to ARDS and SILI [5], inspiratory assistance is lower:
  - i. PS=5, PEEP=5-15 cm H<sub>2</sub>O, high V<sub>t</sub> (500-600 mL) resulting in improved dyspnea in the setting of early ARDS following acquired immunodeficiency syndrome [138].
  - ii. PS=7 cm H<sub>2</sub>O, PEEP<10 cm H<sub>2</sub>O to minimize leaks [72]. The V<sub>t</sub> was ~8-9 in the success group vs. 11-12 mL.kg<sup>-1</sup> in the failure group. In contrast, late ARDS is characterized by low V<sub>t</sub> (rapid shallow breathing: ~4.2 mL.kg<sup>-1</sup> [139]).

- iii. In our experience, with a normalized WOB, the “Smartcare”™ software [140] is highly efficient in reducing PS (Drager Evita 4XL or Infinity V500 with Smartcare) [141]. Smartcare reduces PS from a preset level ~6-8 cm H<sub>2</sub>O to a final level ~3-5 cm H<sub>2</sub>O. The inspiratory WOB is almost entirely suppressed with no phasic activation of the sternomastoid muscle and no sternal notch retraction (high PEEP-low PS termed “inverted settings” [36]). Indeed, a meta-analysis suggests that high PEEP-low PS lowers intubation rate from 43 to 25 % (PEEP=8±2 cm H<sub>2</sub>O, PS=7±2 cm H<sub>2</sub>O) [142].
- iv. The reduction in esophageal pressure changes observed in the NIV success group is associated with the following initial settings: PEEP~10 cm H<sub>2</sub>O and PS~10 cm H<sub>2</sub>O adjusted to achieve Vt<9.5 mL.kg<sup>-1</sup> [2]. After 2 h, PS was lowered (~11 cm H<sub>2</sub>O to ~9 cm H<sub>2</sub>O) in the *failure* group to decrease the Vt [143]. Nevertheless, in contrast with our proposed high PEEP-low PS, the observed Vt was ~11 mL.kg<sup>-1</sup> regardless of success or failure (table 2 [2]). When compared to failure, success is associated with lower esophageal pressure change, higher PS~17 cm [143] and similar Vt [2].
- v. in the setting of ARDS, a low inspiratory assistance (PS=6 cm H<sub>2</sub>O) was used to confirm high Vt independent of PS level [144].
- c. *Inspiratory trigger* at the lowest level: surprisingly, under cooperative sedation, delineated below, and normalized drive, no asynchrony is observed (monotonous breathing, no breath stacking, no double triggering).
- d. *Slope of pressure ramp*: The highest possible pressurization time generates a short inspiratory rise time and leads to the shortest and highest inspiratory peak flow [145]. This minimizes inspiratory effort, esophageal pressure change [146], pendelluft, extracapillary fluid filtration, ventilator-patient asynchrony and inspiratory WOB in intubated patients recovering from ARDS [146, 147]. Meeting the high demand at once during early inspiration lowers WOB [147]. When using mask NIV, the slope is typically set at 100-200 ms [148, 149].
- e. *Flow termination* should be achieved with the lowest expiratory trigger (lowest “cycling off”). First, with low compliance, the peak inspiratory flow is reached rapidly. Extremely early peak flow generated by the ventilator will terminate too rapidly the ventilator’s inspiratory flow sooner than the patient’s own in-

spiratory time, resulting in unmet demand and ventilator-patient asynchrony [59, 150]. Conversely, a long ventilator inspiratory time reduces asynchrony [2, 59] and increases Vt [135]. Second, a prolonged ventilator inspiratory time may activate the expiratory muscles to terminate the breath [150]. This leads to forced expiration and increased expiratory WOB [134]. Therefore, the inspiratory time should be neither too long (≤1s in acute distress [151]) nor too short. In the setting of invasive ventilation, cycling off is set from 1% of peak inspiratory flow [59] to 5% [134, 147]. In the setting of NIV, cycling off is 25-30% [2, 82].

## 2. Helmet NIV

- a. *Standard setting*: Helmet NIV was recently reviewed [152]. Ventilatory flow>100 L.min<sup>-1</sup> avoids CO<sub>2</sub> rebreathing (CPAP systems: Series 500, Sea Long Medical System and CaStar, Starmed) [153]. As observed in the setting of HFN/VHFN, high flow increases the PEEP level. This may increase success when early severe diffuse ARDS is considered. By contrast, the helmet achieves less efficient pressurization and ventilator-patient synchrony. Nevertheless, new helmets are more comfortable and perform better [154]. Given the high compliance of the helmet, PS is modified [148]: fastest pressurization time≤50 ms (improved ventilator-patient synchrony), cycling off set at 50% of peak inspiratory flow down to 30% in case of double triggering [152], higher inspiratory assistance (+33-50%) and higher PEEP [71]. With this optimized synchrony, reduced RR, inspiratory effort, WOB, intubation rate and mortality are observed (intubation: mask: 61%; helmet: 18%; mortality: mask: 56%; helmet: 34%) [71].
- b. *Upfront helmet NIV*: Patients with the largest reduction in esophageal change do not require intubation [2]. Patients presenting with an inspiratory effort>10 cm H<sub>2</sub>O despite helmet NIV require intubation [82] (absence of improvement of labored breathing or of esophageal pressure changes [152], dyspnea, worsening oxygenation or ineffective coughing; mortality: 63%). The implication is that patients presenting with hypocapnia, vigorous inspiratory effort and severe lung injury require upfront helmet NIV and close observation to avoid delaying intubation, skipping HFN/VHFN/mask NIV [120]. Indeed, the absence of reduction of esophageal pressure changes (ΔPes) is associated with death under NIV [2]. Nevertheless, simultaneous to optimized physiological management (e.g., helmet), lowering the drive through a multimodal approach is required.

Patients presenting with a low inspiratory effort and small esophageal change on HFN require low PS, to avoid high transpulmonary pressure [82] during helmet NIV. When a high inspiratory effort and large negative esophageal change under HFN are observed, helmet NIV is superior to HFN (P/F $\leq$ 200; shortest pressurization time, PEEP~10-12, PS~8-10 cm H<sub>2</sub>O; reduced dyspnea, intermediate discomfort) [82]. The reduction of inspiratory effort during helmet NIV was larger in patients with the largest inspiratory effort during HFN, linked to inflammation or deteriorating mechanics, but *not* to oxygenation [86]. Accordingly, patients presenting with low PaCO<sub>2</sub><35 mm Hg benefit from helmet NIV, unlike patients with a high PaCO<sub>2</sub>>35 mm Hg [10].

Partial muscle relaxation [144] may represent an additional tool when the negative evolution of esophageal swings leads to helmet NIV combined to a multimodal approach, before a decision to intubate. In patients presenting with ARDS and a high V<sub>t</sub>>8 mL.kg<sup>-1</sup> a rocuronium infusion (5-37 mg over 6-60 min) was titrated to reduce the V<sub>t</sub> (~9 to ~6 mL.kg<sup>-1</sup>, with increased PaCO<sub>2</sub>) and maintained for 2 h under conventional sedation (midazolam or propofol, sufentanil). Neurally adjusted ventilatory assist (NAVA) preserved diaphragmatic activity [144]. Such an approach may be useful in intubated or non-intubated patients under the care of anesthesia personnel with appropriate end tidal CO<sub>2</sub>, V<sub>t</sub>, SaO<sub>2</sub> monitoring. Although time-consuming, it may allow for the multimodal approach to achieve the temperature, agitation, systemic and microcirculation, kidney and metabolic goals under slow alpha-2 agonist sedation. Taken together, this suggests a 2 h window to improve the patient physiologically (HFN, NIV) [2, 72], then an additional 2 h using partial muscle relaxation [144], while running the multimodal approach from admission onwards (Figure 1). Continued or increased labored breathing despite this full-fledged treatment implies intubation, and low PS under continued multimodal approach [9].

### Invasive ventilation, a rescue therapy

The sickest patients may benefit from immediate helmet NIV+multimodal approach. Within 2h, failed NIV leads to intubation+CMV+proning (*only* a “rescue” therapy) with continued multimodal approach. Early SB and upright position are used in the intubated patient as soon as the drive is normalized [9, 39-41]. Severe ARDS caused by e.g. peritonitis or acute pan-

creatitis necessitates upfront invasive ventilation until inflammation resolves. Indeed, all attempts delineated above may fail avoiding intubation, leading to effective invasive ventilation [100] or ECMO [100]. Less severe patients will undergo escalation under multimodal approach: HFN, then VHFN, and finally NIV (Figure 1). This approach may also apply in the setting of moderate septic shock [125].

Within the factors evoking hyperpnea and tachypnea (Equation 1), lung and systemic inflammation, metabolic acidosis and inadequate microcirculation are difficult to control. Many patients are managed with CMV either due to inappropriate NIV set up or inappropriate sedation with anesthetics/opioids, or extensive illness [20]. For example, full physiological support may coexist with high transpulmonary pressure (38 mm Hg), oedema, inflammation, and microemboli (PS=10, PEEP=15 cm H<sub>2</sub>O, ECMO to remove 77% VCO<sub>2</sub>, normalized pH, PaCO<sub>2</sub>, PaO<sub>2</sub>) [155]. Thus, when the drive exceeds the muscle capacity despite a multimodal approach, rigorous clinical criteria for intubation+CMV are needed.

## ■ PATHOPHYSIOLOGY AND HFN/NIV MERGE IN A MULTIMODAL APPROACH

The multimodal approach (Figure 1) is common to HFN, VHFN, NIV and early SB following short term CMV+paralysis [9]. It relies on normalizing the respiratory drive: regardless of the ventilatory tool, the drive is normalized with Equation 1 as a checklist: (V<sub>t</sub>, RR)=f(temperature, agitation, cardiac output, microcirculation, inflammation, lung water-diuresis, systemic pH, PaCO<sub>2</sub>).

### 1. Fever control [156]

A baby lung allows only for baby O<sub>2</sub> consumption (VO<sub>2</sub>) requirements. Thus, to reduce VO<sub>2</sub>, temperature is lowered to 36< $\theta$ <35°C i.e., the lowest temperature of human at night. In patients with reduced cardioventilatory reserve, VO<sub>2</sub> is lowered [157] (~8-10% per °C [158] e.g., minus ~30% from 39.5 to 35.5°C). In ARDS patients, fever control is associated with improved survival [156]. Furthermore, in healthy volunteers, adrenaline infusion increases VO<sub>2</sub> and V<sub>t</sub> (respectively: +11; +17% [159]) and the inspiratory flow [159], unlike a reduced drive. As the ARDS patient is often septic and requires vasopressors, they further increase VO<sub>2</sub>.



By contrast, alpha-2 agonists lower a) the activation threshold of cold defense effectors (“set point”) [160-162] b) the temperature by  $>1^{\circ}\text{C}$  in healthy volunteers [163] c) energy expenditure and  $\text{VO}_2$  by  $\sim 15\text{-}18\%$  [163, 164] d) muscular tremor [165] and  $\text{VO}_2$ , when baseline is high [166, 167]. Upon admission, paracetamol and external cooling are immediately followed by the administration of an alpha-2 agonist.

## 2. Cooperative sedation

Agitation independent of the ventilatory failure (such as anxiety, delirium, pain) is to be addressed. Dexmedetomidine or clonidine are administered as *first-line* sedatives to stringent quietness ( $-2 < \text{RASS} < 0$ ; up to the “ceiling effect”: dexmedetomidine or clonidine:  $1.5$  or  $2 \mu\text{g}\cdot\text{kg}\cdot\text{h}^{-1}$  respectively; *no* bolus administration; *starting with low doses and titrating slowly*; *fill them up* when hypovolemia is present; *open them up* if microcirculation is compromised [15-17]). The shorter half-life of dexmedetomidine facilitates nursing care (De Kock, personal communication). Alpha-2 agonists *combine* cardiac and vascular sympatholytic [168] and cardiac parasympathomimetic [169] actions, thus normalizing many factors within Equation 1. They evoke also sedation [170-172], slow wave sleep [173], normalize respiratory drive [174] with spontaneous breathing [39, 41], indifference to pain (“analgnesia” [175]) and to psychosocial or environmental stimuli (“imperturbability of mind”: ataraxia) [172], prevent delirium [176-178], reduce reactivity to noxious stimulus [179], especially in addict [180], young, combative patients. Importantly, alpha-2 agonists do not depress the respiratory generator (“generator”) [174]. The generator achieves adequate SB and NIV [181] without asynchrony and respiratory depression [163, 182]: a low  $V_t$  is observed with low or normal RR, according to temperature ( $35 < \theta < 36^{\circ}\text{C}$ ). Indifference is achieved allowing for physiotherapy and continuous HFN/NIV [181, 183, 184] for days, *without* masking failure. Alpha-2 agonists lower the activity of the vasomotor center [185] and cardiac and vascular, arterial and venous, sympathetic activity, reduce the duration of CMV [13] and CCU stay [186], improve systolic [187] and diastolic [188] functions, normalize microcirculation [189], increase lactate clearance [190-192], lower noradrenaline requirement [193-198]. However, alone, alpha-2 agonists are useless. Only *combined* respiratory, ventilatory, circulatory, and autonomic interventions yield efficacy.

*Supplementation:* To achieve  $-2 < \text{RASS} < 0$  and HFN/NIV for days, and given a ceiling effect [199], supple-

mentation is sometimes required (“breakthrough”: haloperidol  $2.5\text{-}10 \text{ mg i.v. bolus}$ ; infusion: haloperidol  $50 \text{ mg}/48 \text{ mL}$ ;  $0.25$  to  $2 \text{ mL}\cdot\text{h}^{-1}$  [15-17]). Given the depression of the generator evoked by midazolam [174], propofol and opioids, we advise against anesthetics and opioids. They depress the drive, impose closer observation and complicate the management. In addition, hyperpnea may resume after curare or sedation withdrawal [200]. Enforcing sleep-wake cycle is crucial [173].

*Pain* management differ between medical and surgical patients, with medical patients typically requiring fewer analgesics compared to surgical patients. Opioid-free analgesia can be employed to avoid respiratory depression and SB suppression (e.g., ketamine  $50 \text{ mg} + \text{nefopam } 100 \text{ mg} + \text{tramadol } 400 \text{ mg}$ ,  $48 \text{ mL}$ ,  $0.1\text{-}2 \text{ mL}\cdot\text{h}^{-1}$  [201]). Tramadol, being a weak opioid, has minimal respiratory depression effects. Cognition in elderly (nefopam) and acute kidney injury (tramadol) patients lead to rapidly lower the doses. The need for opioid-free analgesia typically decreases within  $24\text{-}72\text{h}$  following administration of alpha-2 agonists.

*Cardio-respiratory coupling* [44, 45] and *sympathetic normalization*: First, there is a coordination between inspiratory phrenic and cervical sympathetic activity [202] (“respiratory-cardiovascular coupling”). Partial asphyxia evokes sympathetic activity throughout inspiration and expiration [202], in line with inadequate sympathetic hyperactivity in the setting of ARDS. Second, the interaction is also from the vasomotor center to the respiratory generator. Third, volume and vasopressors normalize the hypotension and the baroreflex-mediated sympathetic vascular hyperactivity. Following normalizing brain stem cardio-respiratory activity, attention can be focused on optimizing ventilatory mechanics, using appropriate tools (HFN, high PEEP-low PS, PEEP+CMV).

## 3. Normalized cardiac output (CO)

Alpha-2 agonists should not be used in cases of hypovolemia, sick sinus syndrome and atrio-ventricular block [15-17]. Positive pressure ventilation and PEEP require volume expansion to prevent hypotension and the need for vasopressors [203] as well as to avoid a pseudo-normalized intrapulmonary shunt [4].

a. Adequate CO and adequate lung perfusion (Q) are necessary to normalize shunt. This also requires sufficient PEEP to achieve proper end-expiratory  $\text{O}_2$  diffusion (VA) [4]. Firstly, upfront normalization of CO enhances pulmonary flow (Q); second, high



PEEP recruits ventilated alveoli (VA). Together, this normalizes the VA/Q distribution and improves oxygenation (patient 10 in [4]).

b. Conversely, a pseudo-normalized shunt results from inadequate CO. First, high PEEP reduces CO, leading to decreased flow to unventilated alveoli, and an increased VA/Q ratio. Secondly, high PEEP increases the ventilation to unperfused alveoli, causing an increase in dead space [92]. As a result, despite an elevated PaO<sub>2</sub>, the shunt remains “pseudo-normalized” [4], as the skewed VA/Q distribution persists unchanged by PEEP itself, and the low VA/Q does not improve.

To achieve adequate VA/Q, first, iterative echocardiography monitors the ventilation-induced changes in vena cava diameter, the right ventricular dilation, the mitral and aortic flows, the left ventricular [LV] contractility and the presence of foramen ovale (present in ~20% of the patients [204]). Various tools as volume, vasopressor, inotrope, pulmonary vasodilator are used to achieve adequate CO, mixed venous saturation, CO<sub>2</sub> gap, pH and lactate. Additionally, the combination of PEEP and SB acts synergistically. SB evokes diaphragmatic compression of the hepatosplanchnic blood [205] enhancing venous return, while PEEP decreases LV afterload [206]. Second, in addition to arterial and venous gases, impedance tomography or lung echography may assist in observing adequate VA.

*Sympathetic normalization and improved microcirculation:* First, the heightened vascular sympathetic activity is associated with high lactate [207]. The alpha-2 agonists normalize the sympathetic activity, the microcirculation [189] and the lactate concentration [189-192]. Systemic and regional metabolic acidosis is normalized within ~3-6 h, lowering peripheral inflammation and respiratory drive. Lastly, acute kidney injury and associated metabolic acidosis are managed with renal replacement therapy. In summary, *counterintuitively*, the treatment approach for ARDS prioritizes circulatory intervention [4, 46, 203, 208, 209] followed by ventilatory strategy.

#### 4. Inflammation

Patients have transitioned from young trauma patients with preserved immune system at baseline and heading into severe delayed injury-acquired immunodeficiency [210], to elderly patients presenting with chronic baseline heightened inflammation, such as those with COVID-ARDS. Acute inflammation can result from

The Journal of Critical Care Medicine 2024;10(4) • 303  
conditions like sepsis, emphasizing the importance of early source control, or systemic acidosis, or impaired ventilatory mechanics (SILI or VILI).

a. Direct immuno-modulation can be targeted (e.g., anti-IL-6) or non-targeted (e.g., steroids). Both address the non-mechanical inflammation caused by the disease (e.g., steroids and SARS-CoV2 [211]) or the syndrome (e.g., systemic sepsis). In addition, steroids may address the inflammation caused by atelectrauma and SILI.

b. Indirect immuno-modulation: alpha-2 agonists present *indirect* systemic anti-inflammatory effects, a facet too often overlooked [195, 212-219]. They normalize heightened sympathetic hyperactivity, and upregulate beta-adrenergic receptors on lymphocytes [220]. This mechanism may extend to normalizing the functioning of all adrenergic receptors on all immune-competent cells. This may alleviate immuno-paralysis.

c. Mechanical inflammation and SILI: Reduction of esophageal pressure changes is co-related to Vt reduction and radiologic improvement, respectively after 12 and 24 h [2]. Therefore, a normalized drive normalizes the WOB and suppresses SILI [5], early on.

#### 5. Lung water

Reducing lung water is crucial [221, 222] when inflammation [223] play a significant role, such as in high permeability edema or large negative esophageal changes. Once CO is normalized, volume infusion should be minimized. Indeed, in the setting of SB, low Vt and compliance [222], a ~10-15% CO increase to passive leg raising does *not* necessarily indicate the need for further hydration. To minimize lung water, the overall response is considered, at variance with BP or CO themselves: mottling, capillary refill time [224], urine output, venous SO<sub>2</sub>, lactate, CO<sub>2</sub> gap, vena cava ventilatory changes.

Additionally, a) SB facilitates better lymphatic drainage compared to CMV [225] b) sympathetic blockade reduces pulmonary vein pressure and lung edema [226] c) alpha-2 agonists evoke diuresis through an anti-ADH effect [227]. The issue is not anymore the total volume of fluids administered during early resuscitation or the first day on admission, but the overall *balance* of fluids and weight achieved after 24, 48, 72 h d) following organophosphate poisoning, clonidine suppresses capillary filtration, thus pulmonary edema [228]. f) following lung contusion, clonidine improves inflammation [229].

## 6. CO<sub>2</sub>

Hypocapnia is an ominous sign in the setting of early ARDS [72]. PaCO<sub>2</sub> is lower when NIV failure occurs [2, 72], *irrespective* of P/F (>200 [72]; 101-170 [2]). This hypocapnia is close to the apneic threshold (healthy volunteer: ~30-35 mm Hg; NIV failure: 32 mm Hg [72]; high inflammatory status e.g. COVID: ≤30 mm Hg). This suggests switching early to helmet NIV [82, 120].

The striking observation is the occurrence of hyperpnea *and* hypocapnia, below the apneic threshold [230, 231]. Indeed, the threshold is overridden by systemic acidosis or central nervous system inflammation or stimulation of lung receptors [42, 43]. Athletes enduring Vt≥3 L, minute ventilation>160 L.min<sup>-1</sup> and esophageal pressure changes≥60 cm H<sub>2</sub>O for hours [77, 119, 232] suggest that increased Vt *per se* is not detrimental, but rather inflammation plays a significant role. Could this be a consequence of pH, PaCO<sub>2</sub> or metabolic or cortical excitatory inputs onto the respiratory generator? If so, the respiratory generator should be made refractory to psychosocial stimuli generated by the CCU environment *without* suppressing respiratory genesis itself [174], and SB. This approach aims to alleviate increased respiratory drive and sympathetic hyperactivity, without resorting to general anesthesia and paralysis.

In COVID-ARDS, under paralysis+CMV, micro- or macrothrombi leads to high dead space, hypercapnia and a high respiratory drive: a low normal temperature (35-36°C) will help normalizing the VCO<sub>2</sub> and hypercapnic drive, allowing for SB, under HFN/NIV.

## 7. O<sub>2</sub>

Hypoxemia, silent without or with overt failure, requires immediate treatment. Nevertheless, alleviating hypoxemia is not the ultimate objective:

- a. Improved oxygenation and reduced mortality are unrelated [233]. Thus, low SaO<sub>2</sub> alone is not an indication for intubation [21]; rather labored breathing and impending/overt failure are.
- b. In rats, inflammation increases in response to acute hypoxia, *independent* of the degree of hypoxemia [234]. To address increased WOB, correction of hypoxemia *per se* is not the immediate goal.
- c. In late-stage ARDS, hypoxemia is associated with increased RR and reversed by high FiO<sub>2</sub> [78]. This holds true in early ARDS: in non-intubated non-paralyzed patients, the hypoxic drive should be suppressed by combining high FiO<sub>2</sub> with the highest PEEP achievable with HFN/NIV. Permissive hypoxemia is

avoided to lower Vt and RR, ideally without hyperoxemia (SaO<sub>2</sub>≥92-100%: roughly the flat portion of the dissociation curve).

- d. Hypoxemia act as a *transient* stimulus, briefly enhancing the ventilatory response to hypercapnia or metabolic acidosis [74, 235] (“*hypoxic ventilatory decline*”). Given the hypocapnia observed in early ARDS [2, 117], the relevant stimulus is not hypoxemia but systemic acidosis or the metaboreflex (“originating in skeletal muscle activated when blood flow to contracting muscles is insufficient to allow both O<sub>2</sub> delivery and metabolite washout” [3]). Furthermore,
  - a) age and diabetes blunt the response to hypoxemia [235].
  - b) in the setting of early ARDS, silent hypoxemia may occur without dyspnea [73-75, 235].

Rather than simultaneously lowering the FiO<sub>2</sub> and the PEEP [97], they are adjusted *sequentially* [37, 41, 236].

- a. *Lowering FiO<sub>2</sub>*: a) Absorption atelectasis [237] necessitates minimizing the duration of FiO<sub>2</sub>=1 administration. b) The highest possible O<sub>2</sub> flow sets PEEP as high as possible given the leaks observed under HFN/NIV. Hypoxemia improves in most patients with a moderate PEEP (5-15 cm H<sub>2</sub>O) achieved with HFN/VHFN [121, 122]. Subsequently, with the highest achievable PEEP and a successful response to the multimodal approach, FiO<sub>2</sub> is gradually reduced from 1 to 0.4.
- b. *Lowering PEEP*: Under FiO<sub>2</sub>=0.4 and *constant* SaO<sub>2</sub>≥96%, PEEP is gradually reduced from ~15 [122] to ~5 cm H<sub>2</sub>O [121], by flow reduction. As the mechanical properties of the lung improve slowly [238, 239], achieving a SaO<sub>2</sub>≥96% requires patience, in contrast to the rapid effects seen with recruitment maneuvers [95]. If deterioration occurs again, it suggests i) investigating underlying causes such as sepsis, coronary occlusion, delirium ii) implementing helmet NIV in cases of persistent or worsening labored breathing iii) revisiting the entire multimodal approach.

## 8. Position

The supine position worsens sick human (reduced FRC, increased abdominal pressure with atelectasis next to the diaphragm) [237]. Thus, the upright position presents some rationale to improve oxygenation [7]. Nevertheless, the head up position may worsen compliance and driving pressure in late ARDS (“paradoxical” positioning [240]). Furthermore, the rationale for extended upright intervals in a healthy human does not automatically transfer to a sick biped.

To our knowledge, upright has not been documented in the setting of COVID-ARDS. As VHFN/NIV may evoke gastric dilation [2], the intraabdominal pressure should be reduced early (gastric and bladder catheters, enhanced intestinal motility).

## ■ CONCLUSION

This multimodal approach bases itself on progress in the pathophysiology of ARDS [2, 6, 8, 42, 43, 72]. This synthesis of autonomic, respiratory, circulatory and ventilatory physiological advances combines with technological advances to avoid intubation, unless “absolutely necessary” [21]. Would this allow to reap “*the far-reaching benefits of spontaneous yet highly supported ventilation in an awake, animated patient over invasive mechanical ventilation via endotracheal tube*” [71]? A prospective randomized pilot trial, then a larger trial are required to ascertain the working hypotheses delineated above.

## ■ ACKNOWLEDGEMENTS

J Escarment is thanked for comments. C Pichot corrected the legend of figure 1. Style and grammar were corrected using ChatGPT, with corrections verified by the corresponding author. Any flaw bears with the corresponding author.

## ■ AUTHOR CONTRIBUTION

Conception: DL, FP, MG, LQ; writing: FP, DL, MG, LQ.

## ■ CONFLICT OF INTEREST

LQ reports honoraria and unrestricted research grants from Boehringer-Ingelheim, France, UCB Pharma, Belgium and Abbott International, IL, USA [1986-96] and holds US Patent 8 703 697: Method for treating early severe diffuse acute respiratory distress syndrome. LQ is a retired anesthesiologist (reserve), Service de Santé des Armées, Department of Defense. The other authors disclose no conflict of interest.

## ■ REFERENCES

1. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992;267(9):1244-52.
2. Tonelli R, Fantini R, Tabbi L, Castaniere I, Pisani L, Pellegrino MR, et al. Early Inspiratory Effort Assessment by Esophageal Manometry Predicts Noninvasive Ventilation Outcome in De Novo Respiratory Failure. A Pilot Study. Am J Respir Crit Care Med 2020;202(4):558-67.
3. Nobrega AC, O’Leary D, Silva BM, Marongiu E, Piepoli MF, Crisafulli A. Neural regulation of cardiovascular response to exercise: role of central command and peripheral afferents. Biomed Res Int 2014;2014:478965.
4. Dantzker DR, Lynch JP, Weg JG. Depression of cardiac output is a mechanism of shunt reduction in the therapy of acute respiratory failure. Chest 1980;77(5):636-42.
5. Brochard L, Slutsky A, Pesenti A. Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure. Am J Respir Crit Care Med 2017;195(4):438-42.
6. Selickman J, Vrettou CS, Mentzelopoulos SD, Marini JJ. COVID-19-Related ARDS: Key Mechanistic Features and Treatments. J Clin Med 2022;11(16).
7. Dellamonica J, Lerolle N, Sargentini C, Hubert S, Beduneau G, Di Marco F, et al. Effect of different seated positions on lung volume and oxygenation in acute respiratory distress syndrome. Intensive Care Med 2013;39(6):1121-7.
8. Kummer RL, Marini JJ. The Respiratory Mechanics of COVID-19 Acute Respiratory Distress Syndrome-Lessons Learned? J Clin Med 2024;13(7).
9. Petitjeans F, Leroy S, Pichot C, Ghignone M, Quintin L, Longrois D, et al. Improved understanding of the respiratory drive pathophysiology could lead to earlier spontaneous breathing in severe acute respiratory distress syndrome. European Journal of Anaesthesiology and Intensive Care Medicine 2023;2(5):e0030.
10. Munshi L, Mancebo J, Brochard LJ. Noninvasive Respiratory Support for Adults with Acute Respiratory Failure. N Engl J Med 2022;387(18):1688-98.
11. Muriel A, Penuelas O, Frutos-Vivar F, Arroliga AC, Abaira V, Thille AW, et al. Impact of sedation and analgesia during noninvasive positive pressure ventilation on outcome: a marginal structural model causal analysis. Intensive Care Med 2015;41(9):1586-600.
12. Pandharipande PP, Pun B, Herr DI, Maze M, Girard TD, Miller RR, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients : the MENDS randomized controlled trial. Journal of American Medical Association 2007;298:2644-53.
13. Ruokonen E, Parviainen I, Jakob SM, Nunes S, Kaukonen M, Shepherd ST, et al. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Med 2009;35(2):282-90.
14. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. Journal of the American Medical Association 2009;301:489-99.
15. Pichot C, Ghignone M, Quintin L. Dexmedetomidine and

- clonidine: from second- to first-line sedative agents in the critical care setting? *J Intensive Care Med* 2012;27(4):219-37.
16. Longrois D, Petitjeans F, Simonet O, de Kock M, Belliveau M, Pichot C, et al. Clinical Practice: Should we Radically Alter our Sedation of Critical Care Patients, Especially Given the COVID-19 Pandemics? *Rom J Anaesth Intensive Care* 2020;27(2):43-76.
  17. Longrois D, Petitjeans F, Simonet O, Kock M, Belliveau M, Pichot C, et al. How should dexmedetomidine and clonidine be prescribed in the critical care setting? *Rev Bras Ter Intensiva* 2022;33(4):600-15.
  18. Karim HM, Sarc I, Calandra C, Spadaro S, Mina B, Ciobanu LD, et al. Role of Sedation and Analgesia during Noninvasive Ventilation: Systematic Review of Recent Evidence and Recommendations. *Indian J Crit Care Med* 2022;26(8):938-48.
  19. Huang Z, Chen YS, Yang ZL, Liu JY. Dexmedetomidine versus midazolam for the sedation of patients with non-invasive ventilation failure. *Internal Medicine* 2012;51:2299-305.
  20. Tobin MJ, Laghi F, Jubran A. Caution about early intubation and mechanical ventilation in COVID-19. *Ann Intensive Care* 2020;10(1):78.
  21. Tobin MJ. Basing Respiratory Management of COVID-19 on Physiological Principles. *Am J Respir Crit Care Med* 2020;201(11):1319-20.
  22. Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, et al. Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* 2013;368(23):2159-68.
  23. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 2012;307(23):2526-33.
  24. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020;323(20):2052-9.
  25. Tobin MJ, Jubran A, Laghi F. P-SILI as justification for intubation in COVID-19: readers as arbiters. *Ann Intensive Care* 2020;10(1):156.
  26. Papazian L, Aubron C, Brochard L, Chiche JD, Combes A, Dreyfuss D, et al. Formal guidelines: management of acute respiratory distress syndrome. *Ann Intensive Care* 2019;9(1):69.
  27. Hilbert G, Gruson D, Vargas F, Valentino R, Gbikpi-Benissan G, Dupon M, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. *New England Journal of Medicine* 2001;344:481-7.
  28. Antonelli M, Conti G. Noninvasive positive pressure ventilation as treatment for acute respiratory failure in critically ill patients. *Crit Care* 2000;4(1):15-22.
  29. Gattinoni L, Marini JJ, Chiumello D, Busana M, Camporota L. COVID-19: scientific reasoning, pragmatism and emotional bias. *Ann Intensive Care* 2020;10(1):134.
  30. Grieco DL, Maggiore SM, Roca O, Spinelli E, Patel BK, Thille AW, et al. Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS. *Intensive Care Med* 2021;47(8):851-66.
  31. Thille AW, Frat JP. Noninvasive ventilation as acute therapy. *Curr Opin Crit Care* 2018;24(6):519-24.
  32. Constantin JM, Bougle A, Salaun JP, Futier E. Non-invasive ventilation and high-flow nasal oxygenation: Looking beyond extubation failure? *Anaesth Crit Care Pain Med* 2019;38(6):583-4.
  33. Frat JP, Ragot S, Coudroy R, Constantin JM, Girault C, Prat G, et al. Predictors of Intubation in Patients With Acute Hypoxemic Respiratory Failure Treated With a Noninvasive Oxygenation Strategy. *Crit Care Med* 2018;46(2):208-15.
  34. James A, Verdonk F, Bougle A, Constantin JM. Non-invasive ventilation for acute respiratory failure (in COVID-19 patients): the non-ending story? *Anaesth Crit Care Pain Med* 2020;39(5):549-50.
  35. Spinelli E, Marongiu I, Mauri T. Control of Respiratory Drive by Noninvasive Ventilation as an Early Predictor of Success. *Am J Respir Crit Care Med* 2020;202(12):1737-8.
  36. Petitjeans F, Quintin L. Non-invasive Failure in de novo acute hypoxemic respiratory failure: high positive end-expiratory pressure-low PS, i.e. "inverted" settings ? *Crit Care Med* 2016;44(11):e1153-e4.
  37. Petitjeans F, Pichot C, Ghignone M, Quintin L. Early severe acute respiratory distress syndrome: What's going on? Part II: controlled vs. spontaneous ventilation? *Anaesthesiol Intensive Ther* 2016;48(5):339-51.
  38. Petitjeans F, Pichot C, Ghignone M, Quintin L. Building on the Shoulders of Giants: Is the use of Early Spontaneous Ventilation in the Setting of Severe Diffuse Acute Respiratory Distress Syndrome Actually Heretical? *Turk J Anaesthesiol Reanim* 2018;46(5):339-47.
  39. Petitjeans F, Martinez JY, Danguy des Deserts M, Leroy S, Quintin L, Escarmant J. A Centrally Acting Antihypertensive, Clonidine, Sedates Patients Presenting With Acute Respiratory Distress Syndrome Evoked by Severe Acute Respiratory Syndrome-Coronavirus 2. *Crit Care Med* 2020;48(10):e991-e3.
  40. Petitjeans F, Leroy S, Pichot C, Ghignone M, Quintin L, Constantin JM. Does Interrupting Self-Induced Lung Injury and Respiratory Drive Expedite Early Spontaneous Breathing in the Setting of Early Severe Diffuse Acute Respiratory Distress Syndrome? *Crit Care Med* 2022;50(8):1272-6.
  41. Pichot C, Picoche A, Saboya-Steinbach M, Rousseau R, de Guys J, Lahmar M, et al. Combination of clonidine sedation and spontaneous breathing-pressure support upon acute respiratory distress syndrome : a feasibility study in four patients. *Act Anaesthesiol Belg* 2012;63(3):127-33.
  42. Vaporidi K, Akoumianaki E, Telias I, Goligher EC, Brochard L, Georgopoulos D. Respiratory Drive in Critically Ill Patients. Pathophysiology and Clinical Implications. *Am J Respir Crit Care Med* 2020;201(1):20-32.
  43. Spinelli E, Mauri T, Beitler JR, Pesenti A, Brodie D. Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions.



- Intensive Care Med 2020;46(4):606-18.
44. Fisher JP, Zera T, Paton JFR. Respiratory-cardiovascular interactions. *Handb Clin Neurol* 2022;188:279-308.
  45. McMullan S, Pilowsky PM. The effects of baroreceptor stimulation on central respiratory drive: a review. *Respir Physiol Neurobiol* 2010;174(1-2):37-42.
  46. Page B, Vieillard-Baron A, Beauchet A, Aegerter P, Prin S, Jardin F. Low stretch ventilation strategy in acute respiratory distress syndrome: eight years of clinical experience in a single center. *Crit Care Med* 2003;31(3):765-9.
  47. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N Engl J Med* 2020;383(2):120-8.
  48. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. *JAMA* 2020;323(22):2329-30.
  49. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. *Lancet* 1967;2(7511):319-23.
  50. Coudroy R, Frat JP, Boissier F, Contou D, Robert R, Thille AW. Early Identification of Acute Respiratory Distress Syndrome in the Absence of Positive Pressure Ventilation: Implications for Revision of the Berlin Criteria for Acute Respiratory Distress Syndrome. *Crit Care Med* 2018;46(4):540-6.
  51. Tobin MJ. ARDS: hidden perils of an overburdened diagnosis. *Crit Care* 2022;26(1):392.
  52. Ferguson ND, Kacmarek RM, Chiche JD, Singh JM, Hallett DC, Mehta S, et al. Screening of ARDS patients using standardized ventilator settings: influence on enrollment in a clinical trial. *Intensive Care Med* 2004;30(6):1111-6.
  53. Aboab J, Jonson B, Kouatchet A, Taille S, Niklason L, Brochard L. Effect of inspired oxygen fraction on alveolar derecruitment in acute respiratory distress syndrome. *Intensive Care Med* 2006;32(12):1979-86.
  54. Guerin C, Thompson T, Brower R. The ten diseases that look like ARDS. *Intensive Care Med* 2015;41(6):1099-102.
  55. Rouby JJ, Puybasset L, Cluzel P, Richecoeur J, Lu Q, Grenier P. Regional distribution of gas and tissue in acute respiratory distress syndrome. II. Physiological correlations and definition of an ARDS Severity Score. CT Scan ARDS Study Group. *Intensive Care Med* 2000;26(8):1046-56.
  56. Gattinoni L, Caironi P, Cressoni M, Chiumello D, Ranieri VM, Quintel M, et al. Lung recruitment in patients with the acute respiratory distress syndrome. *N Engl J Med* 2006;354(17):1775-86.
  57. Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. *N Engl J Med* 2002;346(17):1281-6.
  58. Kallet RH, Zhuo H, Ho K, Lipnick MS, Gomez A, Matthay MA. Lung Injury Etiology and Other Factors Influencing the Relationship Between Dead-Space Fraction and Mortality in ARDS. *Respir Care* 2017;62(10):1241-8.
  59. Mauri T, Bellani G, Grasselli G, Confalonieri A, Rona R, Patroniti N, et al. Patient-ventilator interaction in ARDS patients with extremely low compliance undergoing ECMO: a novel approach based on diaphragm electrical activity. *Intensive Care Med* 2013;39(2):282-91.
  60. Gattinoni L, Marini JJ, Pesenti A, Quintel M, Mancebo J, Brochard L. The "baby lung" became an adult. *Intensive Care Med* 2016.
  61. Grasselli G, Tonetti T, Protti A, Langer T, Girardis M, Bellani G, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. *Lancet Respir Med* 2020;8(12):1201-8.
  62. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome. *Am J Respir Crit Care Med* 2020;201(10):1299-300.
  63. Mauri T, Spinelli E, Scotti E, Colussi G, Basile MC, Crotti S, et al. Potential for Lung Recruitment and Ventilation-Perfusion Mismatch in Patients With the Acute Respiratory Distress Syndrome From Coronavirus Disease 2019. *Crit Care Med* 2020;48(8):1129-34.
  64. Carvalho AR, Spieth PM, Pelosi P, Beda A, Lopes AJ, Neykova B, et al. Pressure support ventilation and biphasic positive airway pressure improve oxygenation by redistribution of pulmonary blood flow. *Anesth Analg* 2009;109(3):856-65.
  65. Kernan S, Rehman S, Meyer T, Bourbeau J, Caron N, Tobias JD. Effects of dexmedetomidine on oxygenation during one-lung ventilation for thoracic surgery in adults. *Journal of Minimal Access Surgery* 2011;7:227-31.
  66. Huang SQ, Zhang J, Zhang XX, Liu L, Yu Y, Kang XH, et al. Can Dexmedetomidine Improve Arterial Oxygenation and Intrapulmonary Shunt during One-lung Ventilation in Adults Undergoing Thoracic Surgery? A Meta-analysis of Randomized, Placebo-controlled Trials. *Chin Med J (Engl)* 2017;130(14):1707-14.
  67. Wang Y, Gong C, Yu F, Zhang Q. Effect of dexmedetomidine on intrapulmonary shunt in patients with sevoflurane maintained during one-lung ventilation: A case-control study. *Medicine (Baltimore)* 2022;101(46):e31818.
  68. Brochard L, Harf A, Lorino H, Lemaire F. Inspiratory pressure support prevents diaphragmatic fatigue during weaning from mechanical ventilation. *Am Rev Respir Dis* 1989;139(2):513-21.
  69. Tobin MJ. Why Physiology Is Critical to the Practice of Medicine: A 40-year Personal Perspective. *Clin Chest Med* 2019;40(2):243-57.
  70. Tonelli R, Cortegiani A, Marchionni A, Fantini R, Tabbi L, Castaniere I, et al. Nasal pressure swings as the measure of inspiratory effort in spontaneously breathing patients with de novo acute respiratory failure. *Crit Care* 2022;26(1):70.
  71. Patel BK, Wolfe KS, Pohlman AS, Hall JB, Kress JP. Effect of Noninvasive Ventilation Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. *JAMA* 2016;315(22):2435-41.

72. Cardeaux G, Millan-Guilarte T, De Prost N, Razazi K, Abid S, Thille AW, et al. Failure of Noninvasive Ventilation for De Novo Acute Hypoxemic Respiratory Failure: Role of Tidal Volume. *Crit Care Med* 2016;44(2):282-90.
73. Couzin-Frankel J. The mystery of the pandemic's 'happy hypoxia'. *Science* 2020;368(6490):455-6.
74. Kallet RH, Branson RD, Lipnick MS. Respiratory Drive, Dyspnea, and Silent Hypoxemia: A Physiological Review in the Context of COVID-19. *Respir Care* 2022.
75. Tobin MJ, Laghi F, Jubran A. Why COVID-19 Silent Hypoxemia Is Baffling to Physicians. *Am J Respir Crit Care Med* 2020;202(3):356-60.
76. Lujan M, Gomez C, Penuelas O, Ferrando C, Heili-Frades S, Perales J, et al. Multidisciplinary consensus on the management of non-invasive respiratory support in the COVID-19 patient. *Archives of Bronchopneumology (Spain)* 2024.
77. Grieco DL, Menga LS, Eleuteri D, Antonelli M. Patient self-inflicted lung injury: implications for acute hypoxemic respiratory failure and ARDS patients on non-invasive support. *Minerva Anestesiol* 2019;85(9):1014-23.
78. Pesenti A, Rossi N, Calori A, Foti G, Rossi GP. Effects of short-term oxygenation changes on acute lung injury patients undergoing pressure support ventilation. *Chest* 1993;103(4):1185-9.
79. Demoule A, Jung B, Prodanovic H, Molinari N, Chanques G, Coirault C, et al. Diaphragm dysfunction on admission to the intensive care unit. Prevalence, risk factors, and prognostic impact—a prospective study. *Am J Respir Crit Care Med* 2013;188(2):213-9.
80. Aubier M, Trippebach T, Roussos C. Respiratory muscle fatigue during cardiogenic shock. *Journal of applied physiology: respiratory, environmental and exercise physiology* 1981;51(2):499-508.
81. Freebairn R, Hickling KG. Spontaneous breathing during mechanical ventilation in ARDS. *Crit Care Shock* 2005;8(3):61-6.
82. Grieco DL, Menga LS, Raggi V, Bongiovanni F, Anzellotti GM, Tanzarella ES, et al. Physiological Comparison of High-Flow Nasal Cannula and Helmet Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure. *Am J Respir Crit Care Med* 2020;201(3):303-12.
83. Girard TD, Kress JP, Fuchs BD, Thomason JWW, Schweikert WD, Pun BT, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing controlled trial) : a randomised controlled trial. *Lancet* 2008;371:126-34.
84. Strom T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. *Lancet* 2010;375(9713):475-80.
85. Shehabi Y, Chan L, Kadiman S, Alias A, Ismail WN, Tan MA, et al. Sedation depth and long-term mortality in mechanically ventilated critically ill adults: a prospective longitudinal multicentre cohort study. *Intensive Care Med* 2013;39(5):910-8.
86. Spinelli E, Mauri T. Lung and Diaphragm Protection during Noninvasive Respiratory Support. *Am J Respir Crit Care Med* 2020;201(7):875-6.
87. Morais CCA, Koyama Y, Yoshida T, Plens GM, Gomes S, Lima CAS, et al. High Positive End-Expiratory Pressure Renders Spontaneous Effort Noninjurious. *Am J Respir Crit Care Med* 2018;197(10):1285-96.
88. Chen L, Del Sorbo L, Fan E, Brochard L. Reply to Borges: The Plausibility of "Bronchiolotrauma". *Am J Respir Crit Care Med* 2018;197(8):1087-8.
89. Hedenstierna G, Chen L, Brochard L. Airway closure, more harmful than atelectasis in intensive care? *Intensive Care Med* 2020;46(12):2373-6.
90. LoMauro A, Aliverti A. Physiology masterclass: Extremes of age: newborn and infancy. *Breathe (Sheff)* 2016;12(1):65-8.
91. Holzapfel L, Robert D, Perrin F, Blanc PL, Palmier B, Guerin C. Static pressure-volume curves and effect of positive end-expiratory pressure on gas exchange in adult respiratory distress syndrome. *Crit Care Med* 1983;11(8):591-7.
92. Dantzker DR, Brook CJ, Dehart P, Lynch JP, Weg JG. Ventilation-perfusion distributions in the adult respiratory distress syndrome. *Am Rev Respir Dis* 1979;120(5):1039-52.
93. Henzler D, Pelosi P, Bensberg R, Dembinski R, Quintel M, Pielen V, et al. Effects of partial ventilatory support modalities on respiratory function in severe hypoxemic lung injury. *Crit Care Med* 2006;34(6):1738-45.
94. Lachmann B. Open up the lung and keep the lung open. *Intensive Care Med* 1992;18(6):319-21.
95. Borges JB, Carvalho CR, Amato MB. Lung recruitment in patients with ARDS. *N Engl J Med* 2006;355(3):319-20.
96. Pellegrini M, Hedenstierna G, Roneus A, Segelso M, Larsson A, Perchiizzi G. The Diaphragm Acts as a Brake during Expiration to Prevent Lung Collapse. *Am J Respir Crit Care Med* 2017;195(12):1608-16.
97. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* 2004;351(4):327-36.
98. Gattinoni L, Carlesso E, Cressoni M. Selecting the 'right' positive end-expiratory pressure level. *Curr Opin Crit Care* 2015;21(1):50-7.
99. Talmor D, Sarge T, Malhotra A, O'Donnell CR, Ritz R, Lisbon A, et al. Mechanical ventilation guided by esophageal pressure in acute lung injury. *N Engl J Med* 2008;359(20):2095-104.
100. Grasso S, Terragni P, Birocco A, Urbino R, Del Sorbo L, Filippini C, et al. ECMO criteria for influenza A (H1N1)-associated ARDS: role of transpulmonary pressure. *Intensive Care Med* 2012;38(3):395-403.
101. Petty TL. Suspended life or extending death? *Chest* 1998;114(2):360-1.
102. Chanques G, Jaber S, Jung B, Payen JF. Sédation-analgésie en réanimation de l'adulte. *Encyclo Med-Chir, Anesth Rea*

- 2013;10(4):1-12.
103. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med* 2010;363(12):1107-16.
  104. Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, et al. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 2015;372(8):747-55.
  105. Zangrillo A, Gattinoni L. Learning from mistakes during the pandemic: the Lombardy lesson. *Intensive Care Med* 2020;46(8):1622-3.
  106. Slutsky AS, Villar J. Early Paralytic Agents for ARDS? Yes, No, and Sometimes. *N Engl J Med* 2019;380(21):2061-3.
  107. Vaschetto R, Cammarota G, Colombo D, Longhini F, Grossi F, Giovanniello A, et al. Effects of propofol on patient-ventilator synchrony and interaction during pressure support ventilation and neurally adjusted ventilatory assist. *Crit Care Med* 2014;42(1):74-82.
  108. Rasulo FA, Badenes R, Longhitano Y, Racca F, Zanza C, Marchesi M, et al. Excessive Sedation as a Risk Factor for Delirium: A Comparison between Two Cohorts of ARDS Critically Ill Patients with and without COVID-19. *Life (Basel)* 2022;12(12).
  109. Wrigge H, Downs JB, Hedenstierna G, Putensen C. Paralysis during mechanical ventilation in acute respiratory distress syndrome: back to the future? *Crit Care Med* 2004;32(7):1628-9; author reply 9-30.
  110. Putensen C, Zech S, Wrigge H, Zinserling J, Stuber F, Von Spiegel T, et al. Long-term effects of spontaneous breathing during ventilatory support in patients with acute lung injury. *Am J Respir Crit Care Med* 2001;164(1):43-9.
  111. Zhou Y, Jin X, Lv Y, Wang P, Yang Y, Liang G, et al. Early application of airway pressure release ventilation may reduce the duration of mechanical ventilation in acute respiratory distress syndrome. *Intensive Care Med* 2017;43(11):1648-59.
  112. Guerin C, Albert RK, Beitler J, Gattinoni L, Jaber S, Marini JJ, et al. Prone position in ARDS patients: why, when, how and for whom. *Intensive Care Med* 2020;46(12):2385-96.
  113. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? *Crit Care* 2020;24(1):154.
  114. Laier-Groeneveld G, Kurz B, Criée C, Hasenfuss G. High volume, low PEEP and passive hyperventilation without sedatives instead of low tidal volume, high PEEP and deep sedation in COVID19 *Europ Resp J* 2020. p. 3431.
  115. Hedenstierna G. Esophageal pressure: benefit and limitations. *Minerva Anestesiol* 2012;78(8):959-66.
  116. L'Her E, Deye N, Lellouche F, Taille S, Demoule A, Fraticelli A, et al. Physiologic effects of noninvasive ventilation during acute lung injury. *Am J Respir Crit Care Med* 2005;172(9):1112-8.
  117. Carreaux G, de Prost N, Razazi K, Mekontso Dessap A. The authors reply. *Crit Care Med* 2016;44(11):e1154.
  118. Rittayamai N, Brochard L. Recent advances in mechanical ventilation in patients with acute respiratory distress syndrome. *Eur Respir Rev* 2015;24(135):132-40.
  119. Marini JJ. Unproven clinical evidence in mechanical ventilation. *Curr Opin Crit Care* 2012;18(1):1-7.
  120. Thille AW, Yoshida T. High Pressure versus High Flow: What Should We Target in Acute Respiratory Failure? *Am J Respir Crit Care Med* 2020;201(3):265-6.
  121. Parke R, McGuinness S, Eccleston M. Nasal high-flow therapy delivers low level positive airway pressure. *Br J Anaesth* 2009;103(6):886-90.
  122. Parke RL, Bloch A, McGuinness SP. Effect of Very-High-Flow Nasal Therapy on Airway Pressure and End-Expiratory Lung Impedance in Healthy Volunteers. *Respir Care* 2015;60(10):1397-403.
  123. Basile MC, Mauri T, Spinelli E, Dalla Corte F, Montanari G, Marongiu I, et al. Nasal high flow higher than 60 L/min in patients with acute hypoxemic respiratory failure: a physiological study. *Crit Care* 2020;24(1):654.
  124. Oczkowski S, Ergon B, Bos L, Chatwin M, Ferrer M, Gregoretti C, et al. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. *Eur Respir J* 2022;59(4).
  125. Mauri T, Spinelli E, Pavlovsky B, Grieco DL, Ottaviani I, Basile MC, et al. Respiratory Drive in Patients with Sepsis and Septic Shock: Modulation by High-flow Nasal Cannula. *Anesthesiology* 2021;135(6):1066-75.
  126. Anderson Nj, Cassidy PE, Janssen LL, Dengel DR. Peak Inspiratory Flows of Adults Exercising at Light, Moderate and Heavy Work Loads. *Journal of the International Society for Respiratory Protection* 2006;23:53-63.
  127. Ritchie JE, Williams AB, Gerard C, Hockey H. Evaluation of a humidified nasal high-flow oxygen system, using oxygraphy, capnography and measurement of upper airway pressures. *Anaesth Intensive Care* 2011;39(6):1103-10.
  128. Montiel V, Robert A, Robert A, Nabaoui A, Marie T, Mestre NM, et al. Surgical mask on top of high-flow nasal cannula improves oxygenation in critically ill COVID-19 patients with hypoxemic respiratory failure. *Ann Intensive Care* 2020;10(1):125.
  129. Duprez F, Bruyneel A, Machayekhi S, Drognet M, Bouckaert Y, Brimiouille S, et al. The Double-Trunk Mask Improves Oxygenation During High-Flow Nasal Cannula Therapy for Acute Hypoxemic Respiratory Failure. *Respir Care* 2019;64(8):908-14.
  130. Mauri T, Spinelli E, Mariani M, Guzzardella A, Del Prete C, Carlesso E, et al. Nasal High Flow Delivered within the Helmet: A New Noninvasive Respiratory Support. *Am J Respir Crit Care Med* 2019;199(1):115-7.
  131. Friesen RM, Raber MB, Reimer DH. Oxygen concentrators: a primary oxygen supply source. *Can J Anaesth* 1999;46(12):1185-90.
  132. Wrigge H, Reske AW. Patient-ventilator asynchrony: adapt the ventilator, not the patient! *Crit Care Med* 2013;41(9):2240-1.
  133. Marini JJ, Rodriguez RM, Lamb V. The inspiratory workload of patient-initiated mechanical ventilation. *Am Rev Respir Dis* 1986;134(5):902-9.

134. Tokioka H, Tanaka T, Ishizu T, Fukushima T, Iwaki T, Nakamura Y, et al. The effect of breath termination criterion on breathing patterns and the work of breathing during pressure support ventilation. *Anesth Analg* 2001;92(1):161-5.
135. MacIntyre NR, Ho LI. Effects of initial flow rate and breath termination criteria on pressure support ventilation. *Chest* 1991;99(1):134-8.
136. Pichot C, Petitjeans F, Ghignone M, Quintin L. Swift recovery of severe acute hypoxemic respiratory failure under non-invasive ventilation. *Anaesthesiol Intensive Ther* 2015;47(2):138-42.
137. Bellani G, Grassi A, Sosio S, Foti G. Plateau and driving pressure in the presence of spontaneous breathing. *Intensive Care Med* 2019;45(1):97-8.
138. Anjos CF, Schettino GP, Park M, Souza VS, Scalabrini Neto A. A randomized trial of noninvasive positive end expiratory pressure in patients with acquired immune deficiency syndrome and hypoxemic respiratory failure. *Respir Care* 2012;57(2):211-20.
139. Kallet RH, Hemphill JC, 3rd, Dicker RA, Alonso JA, Campbell AR, Mackersie RC, et al. The spontaneous breathing pattern and work of breathing of patients with acute respiratory distress syndrome and acute lung injury. *Respir Care* 2007;52(8):989-95.
140. Dojat M, Harf A, Touchard D, Lemaire F, Brochard L. Clinical evaluation of a computer-controlled pressure support mode. *Am J Respir Crit Care Med* 2000;161(4 Pt 1):1161-6.
141. Galland C, Ferrand FX, Cividjian A, Sergeant A, Pichot C, Ghignone M, et al. Swift recovery of severe hypoxemic pneumonia upon morbid obesity. *Act Anaesthesiol Belg* 2014;65:109-17.
142. Coudroy R, Hoppe MA, Robert R, Frat JP, Thille AW. Influence of Noninvasive Ventilation Protocol on Intubation Rates in Subjects With De Novo Respiratory Failure. *Respir Care* 2020;65(4):525-34.
143. Tonelli R, Tabbi L, Fantini R, Castaniere I, Gozzi F, Busani S, et al. Reply to Tuffet et al. and to Michard and Shelley. *Am J Respir Crit Care Med* 2020;202(5):771-2.
144. Doorduyn J, Nollet JL, Roesthuis LH, van Hees HW, Brochard LJ, Sinderby CA, et al. Partial Neuromuscular Blockade during Partial Ventilatory Support in Sedated Patients with High Tidal Volumes. *Am J Respir Crit Care Med* 2017;195(8):1033-42.
145. Gattinoni L, Vagginelli F, Carlesso E, Taccone P, Conte V, Chiumello D, et al. Decrease in PaCO<sub>2</sub> with prone position is predictive of improved outcome in acute respiratory distress syndrome. *Crit Care Med* 2003;31(12):2727-33.
146. Bonmarchand G, Chevron V, Menard JF, Girault C, Moritz-Berthelot F, Pasquis P, et al. Effects of pressure ramp slope values on the work of breathing during pressure support ventilation in restrictive patients. *Crit Care Med* 1999;27(4):715-22.
147. Chiumello D, Pelosi P, Taccone P, Slutsky A, Gattinoni L. Effect of different inspiratory rise time and cycling off criteria during pressure support ventilation in patients recovering from acute lung injury. *Crit Care Med* 2003;31(11):2604-10.
148. Vargas F, Thille A, Lyazidi A, Campo FR, Brochard L. Helmet with specific settings versus facemask for noninvasive ventilation. *Crit Care Med* 2009;37(6):1921-8.
149. Carreaux G, Lyazidi A, Cordoba-Izquierdo A, Vignaux L, Jolliet P, Thille AW, et al. Patient-ventilator asynchrony during noninvasive ventilation: a bench and clinical study. *Chest* 2012;142(2):367-76.
150. Brochard L. Pressure-support ventilation: still a simple mode? *Intensive Care Med* 1996;22(11):1137-8.
151. Kacmarek RM. NIPPV: patient-ventilator synchrony, the difference between success and failure? *Intensive Care Med* 1999;25(7):645-7.
152. Buell KG, Patel BK. Helmet noninvasive ventilation in acute hypoxic respiratory failure. *Curr Opin Crit Care* 2023;29(1):8-13.
153. Taccone P, Hess D, Caironi P, Bigatello LM. Continuous positive airway pressure delivered with a "helmet": effects on carbon dioxide rebreathing. *Crit Care Med* 2004;32(10):2090-6.
154. Olivieri C, Longhini F, Cena T, Cammarota G, Vaschetto R, Messina A, et al. New versus Conventional Helmet for Delivering Noninvasive Ventilation: A Physiologic, Crossover Randomized Study in Critically Ill Patients. *Anesthesiology* 2016;124(1):101-8.
155. Mauri T, Langer T, Zanella A, Grasselli G, Pesenti A. Extremely high transpulmonary pressure in a spontaneously breathing patient with early severe ARDS on ECMO. *Intensive Care Med* 2016;42(12):2101-3.
156. Schortgen F, Clabault K, Katsahian S, Devaquet J, Mercat A, Deye N, et al. Fever control using external cooling in septic shock: a randomized controlled trial. *Am J Respir Crit Care Med* 2012;185(10):1088-95.
157. Manthous CA, Hall JB, Olson D, Singh M, Chatila W, Pohlman A, et al. Effect of cooling on oxygen consumption in febrile critically ill patients. *Am J Respir Crit Care Med* 1995;151(1):10-4.
158. Young PJ, Saxena M. Fever management in intensive care patients with infections. *Crit Care* 2014;18(2):206.
159. Askanazi J, Forse RA, Weissman C, Hyman AI, Kinney JM. Ventilatory effects of the stress hormones in normal man. *Crit Care Med* 1986;14(7):602-5.
160. Myers RD, Beleslin DB, Rezvani AH. Hypothermia: role of alpha 1- and alpha 2-noradrenergic receptors in the hypothalamus of the cat. *Pharmacology, biochemistry, and behavior* 1987;26(2):373-9.
161. Petitjeans F, Leroy S, Pichot C, Geloën A, Ghignone M, Quintin L. Hypothesis: Fever control, a niche for alpha-2 agonists in the setting of septic shock and severe acute respiratory distress syndrome? *Temperature (Austin)* 2018;5(3):224-56.
162. Mokhtari M, Sistanizad M, Farasatinasab M. Antipyretic Effect of Clonidine in Intensive Care Unit Patients: A Nested Observational Study. *J Clin Pharmacol* 2017;57(1):48-51.
163. Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. *Anesthesiology* 1992;77(6):1125-33.



164. Takahashi H, Nishikawa T, Mizutani T, Handa F. Oral clonidine premedication decreases energy expenditure in human volunteers. *Can J Anaesth* 1997;44(3):268-72.
165. Tremblay LE, Bedard PJ. Effect of clonidine on motoneuron excitability in spinalised rats. *Neuropharmacology* 1986;25:41-6.
166. Quintin L, Viale JP, Annat G, Hoen JP, Butin E, Cottet-Emard JM, et al. Oxygen uptake after major abdominal surgery: effect of clonidine. *Anesthesiology* 1991;74(2):236-41.
167. Liatsi D, Tsapas B, Pampori S, Tsagourias M, Pneumatikos I, Matamis D. Respiratory, metabolic and hemodynamic effects of clonidine in ventilated patients presenting with withdrawal syndrome. *Intensive Care Med* 2009;35(2):275-81.
168. Mermet C, Quintin L. Effect of clonidine on the catechol metabolism in the rostral ventrolateral medulla : an in vivo electrochemical study. *European Journal of Pharmacology* 1991;204:105-7.
169. Toader E, Cividjian A, Quintin L. Recruitment of cardiac parasympathetic activity : effects of clonidine on cardiac vagal motoneurons, pressure lability and cardiac baroreflex slope in rats. *British Journal of Anaesthesia* 2009;102:322-30.
170. Stahle H. A historical perspective: development of clonidine. *Bailliere's Clinical Anaesthesiology* 2000;14(2):236-46.
171. Onesti G, Bock KD, Heimsoth V, Kim KE, Merguet P. Clonidine: a new antihypertensive agent. *American Journal of Cardiology* 1971;28(1):74-83.
172. Dollery CT, Davies DS, Draffan GH, Dargie HJ, Dean CR, Reid JL, et al. Clinical pharmacology and pharmacokinetics of clonidine. *Clin Pharmacol Ther* 1976;19(1):11-7.
173. Alexopoulou C, Kondili E, Diamantaki E, Psarologakis C, Kokkini S, Bolaki M, et al. Effects of dexmedetomidine on sleep quality in critically ill patients: a pilot study. *Anesthesiology* 2014;121(4):801-7.
174. Voituren N, Hilaire G, Quintin L. Dexmedetomidine and clonidine induce long-lasting activation of the respiratory rhythm generator of neonatal mice: possible implication for critical care. *Respir Physiol Neurobiol* 2012;180(1):132-40.
175. Kauppila T, Kempainen P, Tanila H, Pertovaara A. Effect of systemic medetomidine, an alpha-2 adrenoceptor agonist, on experimental pain in humans. *Anesthesiology* 1991;74:3-8.
176. Bohrer H, Bach A, Layer M, Werming P. Clonidine as a sedative adjunct in intensive care. *Intensive Care Medicine* 1990;16:265-6.
177. Carrasco G, Baeza N, Cabre L, Portillo E, Gimeno G, Manzanedo D, et al. Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial. *Crit Care Med* 2016;44(7):1295-306.
178. Maldonado JR, Wysong A, van der Starre PJ, Block T, Miller C, Reitz BA. Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery. *Psychosomatics* 2009;50(3):206-17.
179. Saito J, Amanai E, Hirota K. Dexmedetomidine-treated hyperventilation syndrome triggered by the distress related with a urinary catheter after general anesthesia: a case report. *JA Clin Rep* 2017;3(1):22.
180. Gold MS, Redmond DE, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. *Lancet* 1978;2:599-602.
181. Akada S, Takeda S, Yoshida Y, Nakazato K, Mori M, Hongo T, et al. The efficacy of dexmedetomidine in patients with noninvasive ventilation: a preliminary study. *Anesth Analg* 2008;107(1):167-70.
182. Bailey PL, Sperry RJ, Johnson GK, Eldredge SJ, East KA, East TD, et al. Respiratory effects of clonidine alone and combined with morphine, in humans. *Anesthesiology* 1991;74(1):43-8.
183. Deletombe B, Trouve-Buisson T, Godon A, Falcon D, Giorgis-Allemand L, Bouzat P, et al. Dexmedetomidine to facilitate non-invasive ventilation after blunt chest trauma: A randomised, double-blind, crossover, placebo-controlled pilot study. *Anaesth Crit Care Pain Med* 2019;38(5):477-83.
184. Talpos MT, Rasson A, De Terwangne C, Simonet O, Taccone FS, Vallot F. Early Prediction of High-Flow Oxygen Therapy Failure in COVID-19 Acute Hypoxemic Respiratory Failure: A Retrospective Study of Scores and Thresholds. *Cureus* 2022;14(11):e32087.
185. Sun MK, Guyenet P. Effect of clonidine and gamma-aminobutyric acid on the discharges of medullo-spinal sympathoexcitatory neurons in the rat. *Brain Research* 1986;368:1-17.
186. Zhang Z, Chen K, Ni H, Zhang X, Fan H. Sedation of mechanically ventilated adults in intensive care unit: a network meta-analysis. *Sci Rep* 2017;7:44979.
187. Giles TD, Iteld BJ, Mautner RK, Rognoni PA, Dillenkoffer RL. Short-term effects of intravenous clonidine in congestive heart failure. *Clin Pharmacol Ther* 1981;30:724-8.
188. Stefanadis C, Manolis A, Dernellis J, Tsioufis C, Tsiamis E, Gavras I, et al. Acute effect of clonidine on left ventricular pressure-volume relation in hypertensive patients with diastolic heart dysfunction. *J Hum Hypertens* 2001;15(9):635-42.
189. Miranda ML, Balarini MM, Bouskela E. Dexmedetomidine attenuates the microcirculatory derangements evoked by experimental sepsis. *Anesthesiology* 2015;122(3):619-30.
190. Kulka PJ, Tryba M, Reimer T, Weisser H. Clonidine prevents tissue-malperfusion during extracorporeal circulation. *Anesth Analg* 1996;82:S254.
191. De Kock M, Laterre PF, Van Obbergh L, Carlier M, Lerut J. The effects of intraoperative intravenous clonidine on fluid requirements, hemodynamic variables, and support during liver transplantation : a prospective, randomized study. *Anesth Analg* 1998;86:468-76.
192. Miyamoto K, Nakashima T, Shima N, Kato S, Ueda K, Kawazoe Y, et al. Effect of Dexmedetomidine on Lactate Clearance in Patients with Septic Shock: A Sub-Analysis of a Multicenter Randomized Controlled Trial. *Shock* 2017;50(2):162-6.
193. Pichot C, Geloën A, Ghignone M, Quintin L. Alpha-2 agonists to reduce vasopressor requirements in septic shock? *Med Hypotheses* 2010;75:652-6.

194. Geloan A, Chapelier K, Cividjian A, Dantony E, Rabilloud M, May CN, et al. Clonidine and dexmedetomidine increase the pressor response to norepinephrine in experimental sepsis: a pilot study. *Crit Care Med* 2013;41(12):e431-8.
195. Leroy S, Aladin L, Laplace C, Jalem S, Rosenthal J, Abrial A, et al. Introduction of a centrally anti-hypertensive, clonidine, reduces noradrenaline requirements in septic shock caused by necrotizing enterocolitis. *Am J Emerg Med* 2017;35(2):e3-377.
196. Morelli A, Sanfilippo F, Arnemann P, Hessler M, Kampmeier TG, D'Egidio A, et al. The Effect of Propofol and Dexmedetomidine Sedation on Norepinephrine Requirements in Septic Shock Patients: A Crossover Trial. *Crit Care Med* 2018.
197. Gheibi S, Ala S, Heydari F, Salehifar E, Abbaspour Kasgari H, Moradi S. Evaluating the Effect of Dexmedetomidine on Hemodynamic Status of Patients with Septic Shock Admitted to Intensive Care Unit: A Single-Blind Randomized Controlled Trial. *Iran J Pharm Res* 2020;19(4):255-63.
198. Cioccarri L, Luethi N, Bailey M, Shehabi Y, Howe B, Messmer AS, et al. The effect of dexmedetomidine on vasopressor requirements in patients with septic shock: a subgroup analysis of the Sedation Practice in Intensive Care Evaluation [SPICE III] Trial. *Crit Care* 2020;24(1):441.
199. Venn RM, Newman PJ, Grounds RM. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. *Intens Care Med* 2003;29:201-7.
200. Leray V, Bourdin G, Flandreau G, Bayle F, Wallet F, Richard JC, et al. A case of pneumomediastinum in a patient with acute respiratory distress syndrome on pressure support ventilation. *Respir Care* 2010;55(6):770-3.
201. Pichot C, Longrois D, Ghignone M, Quintin L. Dexmédetomidine et clonidine : revue de leurs propriétés pharmacodynamiques en vue de définir la place des agonistes alpha-2 adrénergiques dans la sédation en réanimation. *Ann Franc Anesth Rea* 2012;31(11):876-96.
202. Adrian ED, Bronk DW, Phillips G. Discharges in mammalian sympathetic nerves. *J Physiol* 1932;74(2):115-33.
203. Quenot JP, Binquet C, Pavon A. Cardiovascular collapse: lack of understanding or failure to anticipate heart-lung interaction? *Reanimation (Paris)* 2012;21:710-4.
204. Millington SJ, Cardinal P, Brochard L. Setting and Titrating Positive End-Expiratory Pressure. *Chest* 2022;161(6):1566-75.
205. Permutt S. Circulatory effects of weaning from mechanical ventilation: the importance of transdiaphragmatic pressure. *Anesthesiology* 1988;69(2):157-60.
206. Pinsky MR, Matuschak GM, Klain M. Determinants of cardiac augmentation by elevations in intrathoracic pressure. *J Appl Physiol* (1985) 1985;58(4):1189-98.
207. Garcia-Alvarez M, Marik P, Bellomo R. Stress hyperlactataemia: present understanding and controversy. *Lancet Diabetes Endocrinol* 2014;2(4):339-47.
208. Mekontso Dessap A, Boissier F, Leon R, Carreira S, Campo FR, Lemaire F, et al. Prevalence and prognosis of shunting across patent foramen ovale during acute respiratory distress syndrome. *Crit Care Med* 2010;38(9):1786-92.
209. Repesse X, Aubry A, Vieillard-Baron A. On the complexity of scoring acute respiratory distress syndrome: do not forget hemodynamics! *J Thorac Dis* 2016;8(8):E758-64.
210. Venet F, Cour M, Rimmelé T, Viel S, Yonis H, Coudereau R, et al. Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome. *Crit Care* 2021;25(1):140.
211. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* 2021;384(8):693-704.
212. Xu B, Makris A, Thornton C, Ogle R, Horvath JS, Hennessy A. Antihypertensive drugs clonidine, diazoxide, hydralazine and furosemide regulate the production of cytokines by placentas and peripheral blood mononuclear cells in normal pregnancy. *J Hypertens* 2006;24(5):915-22.
213. von Dossow V, Baehr N, Moshirzadeh M, von Heymann C, Braun JP, Hein OV, et al. Clonidine attenuated early proinflammatory response in T-cell subsets after cardiac surgery. *Anesth Analg* 2006;103(4):809-14.
214. Ueki M, Kawasaki T, Habe K, Hamada K, Kawasaki C, Sata T. The effects of dexmedetomidine on inflammatory mediators after cardiopulmonary bypass. *Anaesthesia* 2014;69(7):693-700.
215. Li B, Li Y, Tian S, Wang H, Wu H, Zhang A, et al. Anti-inflammatory Effects of Perioperative Dexmedetomidine Administered as an Adjunct to General Anesthesia: A Meta-analysis. *Sci Rep* 2015;5:12342.
216. Ohta Y, Miyamoto K, Kawazoe Y, Yamamura H, Morimoto T. Effect of dexmedetomidine on inflammation in patients with sepsis requiring mechanical ventilation: a sub-analysis of a multicenter randomized clinical trial. *Crit Care* 2020;24(1):493.
217. Flanders CA, Rocke AS, Edwardson SA, Baillie JK, Walsh TS. The effect of dexmedetomidine and clonidine on the inflammatory response in critical illness: a systematic review of animal and human studies. *Crit Care* 2019;23(1):402.
218. Hyoju SK, Baral B, Jha PK. Central catecholaminergic blockade with clonidine prevent SARS-CoV-2 complication: A case series. *IDCases* 2021;25:e01219.
219. Chen R, Sun Y, Lv J, Dou X, Dai M, Sun S, et al. Effects of Dexmedetomidine on Immune Cells: A Narrative Review. *Front Pharmacol* 2022;13:829951.
220. Zoukos Y, Thomaidis T, Pavitt DV, Leonard JP, Cuzner ML, Mathias CJ. Upregulation of beta adrenoceptors on circulating mononuclear cells after reduction of central sympathetic outflow by clonidine in normal subjects. *Clinical Autonomic Research* 1992;2:165-70.
221. Jozwiak M, Silva S, Persichini R, Anguel N, Osman D, Richard C, et al. Extravascular lung water is an independent prognostic factor in patients with acute respiratory distress syndrome. *Crit Care Med* 2013;41(2):472-80.
222. Monnet X, Teboul JL. Passive leg raising: five rules, not a drop of fluid! *Crit Care* 2015;19:18.
223. Sinha P, Delucchi KL, McAuley DF, O'Kane CM, Matthay MA,

- Calfée CS. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. *Lancet Respir Med* 2020;8(3):247-57.
224. Hernandez G, Ospina-Tascon GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, et al. Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial. *JAMA* 2019;321(7):654-64.
225. Moriondo A, Mukenge S, Negrini D. Transmural pressure in rat initial subpleural lymphatics during spontaneous or mechanical ventilation. *Am J Physiol Heart Circ Physiol* 2005;289(1):H263-9.
226. Dauber IM, Weil JV. Lung injury edema in dogs. Influence of sympathetic ablation. *J Clin Invest* 1983;72(6):1977-86.
227. Herr DL, Sum-Ping ST, England M. ICU sedation after coronary artery bypass graft surgery: dexmedetomidine-based versus propofol-based sedation regimens. *J Cardiothorac Vasc Anesth* 2003;17(5):576-84.
228. Delaunoy A, Gustin P, Vargas M, Ansay M. Protective effect of various antagonists of inflammatory mediators against paraoxon-induced pulmonary edema in the rabbit. *Toxicol Appl Pharmacol* 1995;132(2):343-5.
229. Loftus TJ, Thomson AJ, Kannan KB, Alamo IG, Millar JK, Plazas JM, et al. Clonidine restores vascular endothelial growth factor expression and improves tissue repair following severe trauma. *Am J Surg* 2017;214(4):610-5.
230. Duffin J. The chemoreflex control of breathing and its measurement. *Can J Anaesth* 1990;37(8):933-42.
231. Caruana-Montaldo B, Gleeson K, Zwillich CW. The control of breathing in clinical practice. *Chest* 2000;117(1):205-25.
232. Guenette JA, Witt JD, McKenzie DC, Road JD, Sheel AW. Respiratory mechanics during exercise in endurance-trained men and women. *J Physiol* 2007;581(Pt 3):1309-22.
233. Spinelli E, Mauri T. Why improved PF ratio should not be our target when treating ARDS. *Minerva Anestesiol* 2021;87(7):752-4.
234. Jacono FJ, Peng YJ, Nethery D, Faress JA, Lee Z, Kern JA, et al. Acute lung injury augments hypoxic ventilatory response in the absence of systemic hypoxemia. *J Appl Physiol* (1985) 2006;101(6):1795-802.
235. Akoumianaki E, Vaporidi K, Bolaki M, Georgopoulos D. Happy or Silent Hypoxia in COVID-19-A Misnomer Born in the Pandemic Era. *Front Physiol* 2021;12:745634.
236. Rezoagli E, Bellani G. How I set up positive end-expiratory pressure: evidence- and physiology-based! *Crit Care* 2019;23(1):412.
237. Hedenstierna G, Edmark L. The effects of anesthesia and muscle paralysis on the respiratory system. *Intensive Care Med* 2005;31(10):1327-35.
238. Chiumello D, Coppola S, Froio S, Mietto C, Brazzi L, Carlesso E, et al. Time to reach a new steady state after changes of positive end expiratory pressure. *Intensive Care Med* 2013;39(8):1377-85.
239. Brower RG. Time to reach a new equilibrium after changes in PEEP in acute respiratory distress syndrome patients. *Intensive Care Med* 2013;39(11):2053-5.
240. Selickman J, Crooke PS, Tawfik P, Dries DJ, Gattinoni L, Marini JJ. Paradoxical Positioning: Does "Head Up" Always Improve Mechanics and Lung Protection? *Crit Care Med* 2022;50(11):1599-606.
241. Prewitt RM, Matthay MA, Ghignone M. Hemodynamic management in the adult respiratory distress syndrome. *Clin Chest Med* 1983;4(2):251-68.
242. Tuffet S, Mekontso Dessap A, Carteaux G. Noninvasive Ventilation for De Novo Respiratory Failure: Impact of Ventilator Setting Adjustments. *Am J Respir Crit Care Med* 2020;202(5):769-70.
243. Mauri T, Grasselli G, Suriano G, Eronia N, Spadaro S, Turrini C, et al. Control of Respiratory Drive and Effort in Extracorporeal Membrane Oxygenation Patients Recovering from Severe Acute Respiratory Distress Syndrome. *Anesthesiology* 2016;125(1):159-67.
244. Crotti S, Bottino N, Ruggeri GM, Spinelli E, Tubiolo D, Lissoni A, et al. Spontaneous Breathing during Extracorporeal Membrane Oxygenation in Acute Respiratory Failure. *Anesthesiology* 2017;126(4):678-87.
245. Marini JJ. Can We Always Trust the Wisdom of the Body? *Crit Care Med* 2022;50(8):1268-71.
246. Gattinoni L, Marini JJ, Busana M, Chiumello D, Camporota L. Spontaneous breathing, transpulmonary pressure and mathematical trickery. *Ann Intensive Care* 2020;10(1):88.

## ■ APPENDIX

This overview outlines a step-by-step escalation based on the severity of ARDS (HFN, VHFN, mask NIV, helmet NIV, invasive ventilation). Despite some research addressing these questions, there remains limited knowledge about SB compared to controlled mechanical ventilation with and without paralysis.

### A. Research questions

As of now, there is a lack of data regarding the measurement of plateau pressure (Pplat) during a brief inspiratory hold in patients receiving non-invasive ventilation (NIV) without an endotracheal tube [137]. Lung mechanics must be re-evaluated specifically in the context of SB, both with and without intubation. This includes re-addressing in the setting of NIV all the parameters used for PS in the setting of invasive ventilation.

Is NIV success related to high PEEP and suppressed solid-like behavior and atelectrauma (reduced inspiratory effort consequence of improved mechanics (PEEP))? is NIV success related to adequate inspiratory assistance and unloading the muscles? [36, 86, 117, 143, 242]; are sick patients with a high drive homogeneous to less severe patients?

Delineate physiologically each factor (temperature, agitation, cardiac output, blood pressure, pH, PaCO<sub>2</sub>) involved in labored breathing, hyperpnea and large changes in esophageal pressure before [2, 72] or after [243, 244] intubation? If mortality is lower [39, 41], what is the mechanism: fever control [119, 245]? normalized sympathetic activity? improved microcirculation? lowered lactate? lowered inflammation? extended tolerance to NIV? minimized leaks and higher PEEP? absence of conventional sedation?

A normalized drive normalizes the WOB and suppresses SILI [5], early. Causality should be clarified: i) SILI is the limiting factor in early ARDS [48, 246] ii) increased WOB then overt failure is the limiting factor [20, 21] iii) both.

Readdress the RV and LV performance in the setting of SB vs CMV+GA?

Quantify the WOB vs. SaO<sub>2</sub>, a putative reduction of esophageal pressure changes and reduction of rate of intubation using VHFN > 120 L.min<sup>-1</sup>?

Do pharmacological tools exist to deactivate lung receptors (mechano-, A $\delta$  and C, J) and minimize lung inflammation?

Addressing Vt in the setting of severe diffuse ARDS (2,4, 6, 8, etc. mL.kg<sup>-1</sup>) with or without veno-venous extracorporeal membrane oxygenation (ECMO), with or without low normal temperature (35-36°C)?

Document the effect of supine vs. proning vs. lateral+prone+lateral repositioning (physiology, CT scan, epidemiology)?

Document the effect of passive hyperventilation without sedation [114] on outcome?

Compare and combine tools to individualize PEEP : esophageal balloon vs impedance tomography vs lung echography?

In addition to the nasal prong, insertion of up to 2 prongs through the mouth would achieve O<sub>2</sub> flow ~120-180 L.min<sup>-1</sup>. Do adequate numbers (SaO<sub>2</sub>) translate into improved outcome?

Readdress pressure support vs airway pressure release ventilation.

Assess partial muscle relaxation [144] in the setting of high Vt and helmet NIV on outcome ? does partial muscle relaxation allows for extended observation with improved outcome?

VHFN appears poorly tolerated, after 20 min [123]. The reason is unclear : poor humidification? high expiratory resistance and expiratory WOB [123]?

Heightened sympathetic hyperactivity downregulates beta-adrenergic receptors on lymphocytes; normalized sympathetic activity upregulates beta adrenergic receptors [220]. Would this improve all adrenergic receptors on all immuno-competent cells? Would this lead to improved immuno-paralysis?

### B. Randomized clinical trial

The PICO (patient, intervention, comparison, outcome) question is: does combining new pathophysiological information reduce intubation+controlled mandatory ventilation (CMV)+paralysis+deep sedation and improve outcome in the setting of early ARDS, manpower, bed and anesthetics shortage and mass influx of patients with baseline chronic inflammation (e.g., COVID-ARDS)?

Following a pilot trial, a prospective trial should randomize patients, with outcome as the primary endpoint:

1. Physiology: Patients presenting with high Vt and or large esophageal pressure swings or low P/F to a 2 h helmet trial, followed if negative with partial muscle



relaxation [144] to lower  $V_t \sim 6 \text{ mL.kg}^{-1}$ .

2. Multimodal approach (physiology + pharmacology): Patients presenting with high  $V_t$  and or large esophageal pressure swings or low P/F to a 2 h helmet trial, followed if negative with partial muscle relaxation to lower  $V_t \sim 6 \text{ mL.kg}^{-1}$ , combined to a multimodal approach as delineated in text (figure 1).

3. State-of-the-art: Patients presenting with high  $V_t$  and or large esophageal pressure swings or low P/F to intubation, controlled mechanical ventilation (driving pressure  $< 14 \text{ cm H}_2\text{O}$ , PEEP according to NIH table [97] or better to esophageal balloon [99, 100], general anesthesia+paralysis+proning as the state of the art in severe ARDS.